Podcasts about adaptive biotechnologies

In this condensed version of Shauna Swerland's conversation with Chad Robins from 2019, you'll hear the origin story of Adaptive Biotechnologies, the corporate culture Chad is building there, and what Chad sees as the most important tasks of a CEO.See omnystudio.com/listener for privacy information.

Drs. John Sweetenham and Marc Braunstein discuss practice-changing studies in hematologic malignancies that were featured at the 2024 ASCO Annual Meeting, including the ASC4FIRST trial in chronic myeloid leukemia and IMROZ and CARTITUDE-4 in multiple myeloma.  TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham from UT Southwestern's Harold C. Simmons Comprehensive Cancer Center and host of the ASCO Daily News Podcast. On today's episode, we'll be discussing practice-changing abstracts and other key advances in hematological malignancies that were featured at the 2024 ASCO Annual Meeting. Joining me for this discussion is an old friend, Dr. Marc Braunstein, a hematologist and oncologist from the NYU Langone Perlmutter Cancer Center.  Our full disclosures are available in the transcript of this episode. Marc, it's great to have you back on the podcast again. There were some important studies in the heme space at the Annual Meeting this year, and we're very pleased that you're able to share your takeaways.  Dr. Marc Braunstein: Thank you, John. It's great to be back again. Dr. John Sweetenham: Let's start out, Marc, with LBA6500. This abstract reports the primary results of the ASC4FIRST trial, and this was a trial comparing asciminib with investigator selected tyrosine kinase inhibitors in newly diagnosed patients with chronic myeloid leukemia. Could you tell us a little about the trial and how you think it's going to impact clinical practice? Dr. Marc Braunstein: Absolutely. So, asciminib is an oral tyrosine kinase of the ABL kinase domain. As we know in CML, the BCR-ABL translocation is characteristic of the disease, and asciminib is approved for chronic phase CML with a T315I resistance mutation or for patients who have received 2 or more prior lines of therapy. So the ASC4FIRST trial was a randomized trial of 405 patients with newly diagnosed chronic phase CML who are randomized one to one to receive either asciminib at 80 milligrams once daily, or investigator's choice of a first generation TKI imatinib or one of three second generation TKIs nilotinib, dasatinib, or bosutinib. The primary endpoint of the study was the major molecular response, or MMR, at 48 weeks. Pretty much, the study met its primary endpoint with a 67% rate of MMR at 48 weeks, with asciminib versus 49% in patients treated with the investigator's choice of TKI. And in addition, the major molecular remission or MMR of 4.5, which is a deep remission, those rates were higher as well, with asciminib versus investigator's choice at a rate of 39% versus 21% when comparing the groups. Furthermore, when we looked at toxicity, there were fewer grade 3 or higher adverse events, with the asciminib at 38% versus either 44% with the first generation, or 55% with the second generation TKI, and fewer discontinuations as well with asciminib.  So I think this abstract is practice-changing. I think it offers compelling data to use asciminib upfront for chronic phase CML. Those who don't agree with that sentiment might argue that we want to see longer term follow up. There's a planned follow-up at 96 weeks. We would want to see the rate of progression to acute myeloid leukemia and of course overall survival as well. But I think the abstract certainly shows an improvement in outcomes with asciminib versus our current array of TKIs. Dr. John Sweetenham: Yeah, I think it certainly is, at least at minimum, potentially practice changing. I agree with you. Just one question, and this may be a little bit speculative, but do you have any thoughts about treatment free survival with asciminib and how that might line up against some of the other TKIs? Dr. Marc Braunstein: Yeah, that's a great question. The abstract did not necessarily address that, patients were treated until progression, but we know that with the current landscape of TKIs, that in patients who have achieved a deep MR of 4 or 4.5 for at least 2 years who discontinue their TKI, the rate of relapse is about 50%. The current study, the ASC4FIRST, doesn't address that, but I think it's a really good question about whether, for those patients who have achieved a deep remission, whether they can eventually stop asciminib down the line. Dr. John Sweetenham: Yeah, I guess it's one of those ‘watch this space' things.  So we'll see how the data mature out. And let's move on to what I think is another potentially practice-changing study, at least in certain parts of the world. And that's [the] LBA7000 study in classical Hodgkin lymphoma. As you remember, this was a German Hodgkin lymphoma study group trial which looked at the tolerability and efficacy of a novel regimen, BrECADD versus eBEACOPP for patients with advanced stage classical Hodgkin lymphoma in their study, which is known as GHSG HD21. Can you give us your thoughts and take home messages from this trial? Dr. Marc Braunstein: Yeah, John, absolutely. So the German HD21 study is a phase 3 study of 1,500 patients with classical Hodgkin lymphoma. The majority were stage 3 or 4, 84%, that compared two regimens BEACOPP to BrECADD. The major difference between these 2 groups being that the newer BrECADD regimen swaps out bleomycin for brentuximab vedotin, which is an anti-CD30 antibody drug conjugate. Also, in the BrECADD regimen they eliminate vincristine that's incorporated into BEACOPP. Those are kind of the global differences between these 2 regimens. And when comparing these, they looked at the primary endpoint of progression-free survival. Of note, in this study there was a PET adjusted approach where if patients achieved interim PET negativity after 2 cycles, that was followed by an additional 2 cycles of their treatment as opposed to 4 cycles if they were PET positive after the initial 2 cycles of their respective treatment. And of note, there were similar rates of PET2 negativity between both arms, about 58% in both arms.  So at a median follow-up of 48 months, the 4-year progression-free survival was significantly better with the brentuximab containing BrECADD regimen at 94% versus 91% with a hazard ratio of 0.66. And the overall survival of the BrECADD arm was 98.6%, which is very high and impressive. The 4-year overall survival was similar between the arms at around 98%, but of note, there were fewer severe adverse events with BrECADD, the brentuximab containing arm versus BEACOPP at about 42% versus 59% and interestingly less peripheral neuropathy with the brentuximab containing BrECADD. So we're doing extremely well in treating advanced stage classical Hodgkin lymphoma. So the bar is set very high. But in this study, the rates of progression-free survival and overall survival are very impressive.  While these intensive regimens tend to be used outside of the U.S., there are several notable benefits of the study, including greater than 50% PET2 negativity and high rates of progression-free survival at 4 years. In discussing this abstract, it's worth noting that there are other competing regimens, if you want to call it that, that are more commonly used in the U.S. So the ECHELON-1 study looked at brentuximab AVD compared with ABVD with bleomycin and it was a 94% versus 89% 6-year overall survival rate favoring the brentuximab containing A+AVD regimen. And lastly, more recently, the SWOG S1826 study that hasn't been published but was presented in abstract form looked at nivolumab AVD versus brentuximab AVD at a median follow up of 12 months showed a progression-free survival of 94% versus 86%. And that study still has yet to be published and needs to mature. But both of those regimens are in the NCCN guidelines. So, we're definitely pushing the bar higher in terms of improving responses in treating advanced classical Hodgkin lymphoma. Dr. John Sweetenham: I think that there's no question that these results from BrECADD are very impressive. But I'm taken back to what I think has been a kind of philosophic discussion in Hodgkin lymphoma now for a number of years about balancing disease control and efficacy against the potential short-term and long-term toxicity of the regimens, particularly when you have very effective salvage therapies for those patients who may suffer a relapse. So I think that this is a discussion over whether you take a very intensive, upfront approach to Hodgkin lymphoma versus something that may be less and slightly less intensive. I suspect that's a discussion that's going to continue for a long time. I don't know what you feel, but my own feeling about this is that this study will likely have a major influence over treatment of Hodgkin lymphoma, particularly in western Europe. Less likely in the US.., I would think. I don't know what your thoughts about that are. Dr. Marc Braunstein: Well, it's a great question. In SWOG S1826, that study did include pediatric patients. In HD21, the median age was 31 and did not include pediatric patients. So I think we have to be selective in terms of fitness and which patients may be better suited for different regimens. But I think what all these studies show is certainly when we incorporate novel immunotherapies, whether it's brentuximab vedotin, nivolumab, we improve progression-free survival and even overall survival. Dr. John Sweetenham: Absolutely.  So let's shift gears now and take a look at Abstract 7500, the IMROZ study. This was the study of isatuximab, bortezomib, lenalidomide and dexamethasone versus VRD alone for transplant ineligible patients with newly diagnosed multiple myeloma. I know we discussed this in our preview podcast a few weeks back, Marc, but I just wonder now, having seen the data in more detail, what do you think of the important takeaways? And again, are we looking at a new standard of care? Dr. Marc Braunstein: You know, there are many standards of care in multiple myeloma, but we're always looking to make improvements on the regimens we have at our disposal. So, just to recap, IMROZ is a phase 3 randomized study of the anti-CD38 monoclonal antibody isatuximab with the backbone of bortezomib, lenalidomide, dexamethasone or VRD versus VRD alone, specifically, in transplant ineligible newly diagnosed multiple myeloma patients age less than 80. They studied 446 patients in this study, randomized 3 to 2 to Isa-VRD versus VRD alone, with the primary endpoint of progression free survival. Now, similar to other studies where they included a monoclonal antibody up front, the study met its primary endpoint of improving progression-free survival with the quad regimen containing the monoclonal antibody isatuximab versus VRD alone.  So what was interesting about the study, it's really the first of its kind to be presented that specifically looked at transplant ineligible patients, which is presumably a less fit or perhaps more frail population that wouldn't go on to consolidation with stem cell transplant. And in this study, the progression-free survival at 5 years was 63% versus 45%, clearly superior when you included isatuximab. And the rates of complete remission and MRD negativity were all significantly improved, too. However, that was also met with slightly more grade 3 or higher treatment emergent adverse events, 92% versus 84% in the control arm. There are also 11% grade 5 treatment emergent adverse events with the isatuximab group versus 5.5% with VRD alone. Although there was no major difference in treatment discontinuation. One small caveat worth noting, too, is that high-risk patients in this study, when presented at ASCO, did not necessarily show a difference in benefit, although there wasn't necessarily a detriment either.  So, John, I think that clearly quadruplet regimens are superior in outcomes of efficacy to triplets, even in transplant-ineligible patients. But I think we have to tailor these treatments to individual patients because I think when it comes to transplant-ineligible patients, it's a spectrum of patients who may be more or less fit for quad regimens versus triplet regimens. It's also worth noting, though, that in this study, the patients are really only getting a quad regimen for 4 cycles. They get their Isa-VRD, and then you drop the bortezomib.  So when we think about quads, it's not that they're getting the quad regimen indefinitely, it's really for the induction cycles. But still, I think we have to be aware of potential safety issues. Dr. John Sweetenham: Okay, great. And let's stay on the theme of multiple myeloma, Marc, and talk a little bit about Abstract 7504, which was a subgroup analysis of the CARTITUDE-4 study. This is a report on the use of ciltacabtagene autoleucel versus standard of care in patients with functional high risk multiple myeloma. Can you give us your thoughts on this and maybe put it into a bit of context for us?  Dr. Marc Braunstein: Absolutely, John. It's really a great time to be in the field of multiple myeloma. We're making tremendous progress, but when we think about one of the unmet needs, it's just consistently the high-risk patients who have shorter responses and are at higher risk for poorer outcomes. Just to review, cilta-cel is one of the 2 available anti-BCMA CAR T-cell products available for the treatment of relapsed or refractory multiple myeloma. Very recently, the FDA approved cilta-cel for lenalidomide refractory patients after 2 or more prior lines of therapy based on the CARTITUDE-4 study, which was published by San-Miguel and colleagues in New England Journal of Medicine in July 2023. And that study randomized 419 patients with multiple myeloma with 1 to 3 prior lines of therapy to receive either cilta-cel or physician's choice of standard of care, which was either 1 of 2 triplet regimens, a pomalidomide, bortezomib, dexamethasone or daratumumab, pomalidomide and dexamethasone. It's worth noting that about 25% of the patients in the CARTITUDE-4 study had prior anti-CD38 antibody treatment previously and the carfilzomib was not included in one of the standard-of-care arms, and we know that those regimens containing carfilzomib do increase survival in relapsed myeloma.  Nevertheless, the primary outcome of progression-free survival was not reached in the CAR T-cell arm versus 11.8 months in the standard-of-care arm, with a significant reduction in progression of 74%. So clearly a positive study and CAR T-cell therapy is included in the NCCN guidelines for patients who have an early relapse from their myeloma. The current abstract by Costa et al focused specifically on a subgroup of 79 patients from CARTITUDE-4 in second line of treatment and looked at what they called functional high-risk myeloma, defined as progression of disease within 18 months of initial treatment or after stem cell transplant. Again, the study showed a retained benefit of cilta-cel with significant improvement in progression-free survival either not reached or 12 months with the control standard of care arm, as well as complete remission rate and rates of MRD negativity of 65% versus 10% in the control.  The overall survival outcome was still immature and not presented. Nevertheless, cilta-cel is clearly superior to standard-of-care triplet regimens. I think that for patients with high risk, they clearly derive a benefit from CAR T-cell therapy if they have short progression-free survival after initial therapy.  Dr. John Sweetenham: Thanks, Marc. So let's round this out by talking about another area of unmet need, I guess in a way in a difficult to treat patient group. And that's Abstract 7007, the SYMPATICO study. This is a study which looks at the efficacy and safety of ibrutinib and venetoclax in patients with mantle cell lymphoma who had a mutated TP53. Can you just briefly review this for us and tell us what you think we should be taking away from this studys? Dr. Marc Braunstein: So, mantle cell lymphoma typically has an aggressive behavior, but the subgroup of patients with a P53 mutation tend to have the poorest outcomes and do represent an area of unmet need. Although BTK inhibitors are making important improvements in mantle cell lymphoma, they have yet to be approved in newly diagnosed mantle cell lymphoma. Acalibutinib and zanubrutinib are FDA-approved BTK inhibitors for previously treated mantle cell lymphoma. Ibrutinib was withdrawn from the market in the U.S. for mantle cell lymphoma. Dr. Michael Wang's group presented late-breaking data from the phase 3 SYMPATICO trial at ASH 2023, in which 267 patients with relapsed refractory mantle cell lymphoma were randomized to receive either ibrutinib plus the BCL2 inhibitor venetoclax or ibrutinib plus placebo after 1 to 5 prior lines of therapy. And that study showed a 32 versus 22 months progression-free survival at a median follow up of 51 months. The current abstract, also by Dr. Wang and colleagues, looked at the subgroup of patients who had a P53 mutation and included an open label cohort of 44 patients in the first line of treatment and a relapse refractory cohort of 75 patients, and compared this subgroup of patients with P53 mutation to those without. When we look at the outcomes, the patients who did not have a P53 mutation clearly did better in terms of progression-free survival being not reached in first-line treatment compared to 22 months progression-free survival in those patients with first-line [treatment] with a P53 mutation. As well as in the relapsed refractory setting, the PFS without the P53 mutation was 47 months versus 21 months with the mutation. However, when you look at these patients treated with ibrutinib and venetoclax comparing whether they got treated in first line or the relapse refractory setting, the overall response rates are very similar at about 80% to 90% and the CR rates were very similar at about 55% to 58%, which to me suggests that although patients with P53 mutation do worse than those without it, whether they're treated in the first-line or the relapse setting with this combination of venetoclax, they tend to do somewhat similar, suggesting that you can overcome resistance to prior therapy in the relapse setting. So I think further data are certainly warranted to explore the role of combination therapies that include novel agents such as BTK inhibitors in the first line setting.  It's worth noting that the TRIANGLE study was recently published, and this study looked at including ibrutinib at various phases, including at induction in combination with intensive chemotherapy and during the maintenance phase. And that study showed encouraging outcomes in patients who received ibrutinib even without stem cell transplant compared to those who received stem cell transplant. So the role of BTKIs in mantle cell lymphoma is certainly evolving, and I think it offers a very effective intervention without the same kind of toxicities we see with cytotoxic chemotherapy that's traditionally used in mantle cell lymphoma. But I think the subgroup of patients with P53 mutation in this disease still represent an area of unmet need that unfortunately have worse outcomes. But novel agents may be able to overcome some of those adverse outcomes. Dr. John Sweetenham: Yeah, I agree. I think these are intriguing data, and obviously it needs more follow-up and probably more prospective studies. But nevertheless, I think there are some signals there for sure that need to be followed up on.  Marc, as always, it's great to have your insights on key advances in the heme space from ASCO. An important year this year, and we really appreciate your time and effort in sharing with us your thoughts on what we've learned this year. So thank you as always. Dr. Marc Braunstein: My pleasure. Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the abstract discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's guest:  Dr. Marc Braunstein  @docbraunstein    Follow ASCO on social media:   @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn     Disclosures:  Dr. John Sweetenham:  Consulting or Advisory Role: EMA Wellness  Dr. Marc Braunstein:  Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb/Celgene, Adaptive Biotechnologies, GlaxoSmithKline, ADC Therapeutics, Janssen Oncology, Abbvie, Guidepoint Global, Epizyme, Sanofi, CTI BioPharma Corp  Speakers' Bureau: Janssen Oncology  Research Funding (Institution): Janssen, Celgene/BMS   

Dr. John Sweetenham and Dr. Marc Braunstein look ahead at key abstracts across the spectrum of hematologic malignancies that will be presented at the 2024 ASCO Annual Meeting, including the OPTIC trial in chronic myeloid leukemia, treatment options for transplant-ineligible patients with multiple myeloma, and the 7-year analysis of the ECHELON-1 trial in classical Hodgkin lymphoma. TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham from UT Southwestern's Harold C. Simmons Comprehensive Cancer Center and the host of the ASCO Daily News Podcast. I'm delighted to be joined again this year by Dr. Marc Braunstein, a hematologist and oncologist at the NYU Perlmutter Cancer Center in New York. We're going to be discussing some of the key abstracts in hematologic malignancies that will be featured at the 2024 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode, and disclosures of all guests on the podcast are available at asco.org/DNpod.  Marc, it's great to have you back on the podcast. Dr. Marc Braunstein: It's a pleasure to be back, John.  Dr. John Sweetenham: There are some exciting abstracts to be presented at this year's meeting, and I would like to begin, if we can, with Abstract 6501. As you know, this reports the four-year results from the OPTIC trial of ponatinib in patients with chronic-phase CML and the T315I mutation. Can you tell us about the trial and about these latest follow-up results? Dr. Marc Braunstein: Sure. Well, we've made tremendous progress in managing patients with CML in the past two decades using these oral tyrosine kinase inhibitors such as ponatinib. Ponatinib is a third-generation TKI that has activity in both Philadelphia-positive ALL as well as CML, and can overcome the resistance mutation you mentioned, called the T315I mutation, which is sometimes found following prior TKI therapy. The OPTIC study is a multicenter phase 2 randomized study of various doses of ponatinib in 283 chronic phase CML patients who had received 2 or more prior lines of therapy or those who had the presence of a T315I mutation, with the current analysis examining the major remission at 48 months, PFS, as well as OS. Of note, in this study, after patients have achieved a major remission with a transcript level of 1% or less, the study allowed for dose reduction of ponatinib from the original dose of either 45 milligrams or 30 milligrams to a reduced dose of 15 milligrams.  So, when we look at the results, we find that the patients who had the highest overall response rates and higher rates of molecular remission were those who received the 45-milligram dose. And remember, these patients were allowed to be dose-reduced to the 15-milligram dose once they achieved a molecular remission of 1% or less. In addition, the rates of overall survival were highest in the 45-milligram dose as well. When looking at the T315I subgroup, the rates of molecular remission, the depth of remission, and the rates of progression-free survival, in general, were lower in that subgroup, but still higher in the 45-milligram dose than the 35- milligram dose.  Furthermore, when looking at the rates of treatment-emergent adverse events leading to discontinuation, they were 8% in the 45-milligram dose compared to 14% in the 30-milligram dose and 5% in the patients who only received the 15-milligram dose. The authors have concluded that the 45-milligram dose, with the potential to be reduced to 15 milligrams after achieving 1% or less of the BCR-ABL transcript level, seems to be the right balance between efficacy and safety.  Dr. John Sweetenham: Thanks, Marc. In the longer term, do you think that this study will, in any way, affect the position of ponatinib in the treatment algorithm for CML? Is it going to remain as a second or third-line option, or do you think there's any chance it will be moved up? Dr. Marc Braunstein: Well, that's a great question. There are other TKIs, such as asciminib, that also target the T315I mutation, and that mutation tends to develop after prior first-line or second-line TKI therapy. But given its activity in both ALL and CML, I think it's certainly reasonable to expect that ponatinib will be used in earlier lines of therapy given its efficacy in later lines. Dr. John Sweetenham: Let's change gears and move the focus to acute myeloid leukemia. There has been a lot of discussion around frailty in many different malignancies, but the impact of frailty on outcomes in AML is maybe something that hasn't been quite so well studied. In Abstract 6506, investigators did a population-based study in Ontario, Canada, that assessed the patient's frailty risk and the impact that might have on outcomes. What are your takeaways from this study, and how do you think these data will help optimize treatment decisions?  Dr. Marc Braunstein: Yeah, I'm glad we're talking about this abstract John, because frailty scores are increasingly being used in hematologic malignancies to help guide goals and intensity of care. And as opposed to using age or performance status alone, these composite frailty assessment tools, such as the MFI tool that they used in this particular study, take into account multiple variables that are both physiologic, such as the patient's comorbidities, as well as social, and what kind of support system do they have, and things of that nature. And that accounts for their overall fitness. So, in this retrospective cohort study that was a population-based study in Ontario between 2006 and 2021, they looked at 5,450 patients retrospectively with acute leukemia and grouped those patients into 3 categories based on this frailty index. Patients who are either fit, somewhere in the middle between fit or frail, which they call pre-frail, or frail. And they looked at outcomes such as overall survival, comparing patients who got intensive chemotherapy regimens for induction or those who got non-intensive therapy for induction. Patients in either group could have been assigned to either fit, pre-frail, or frail although there are much more fit patients than those who got intensive induction.  And so, looking at their findings, it was noted that patients who were in the frail category, not entirely unexpectedly, had lower overall survival when compared to those who were fit or pre-frail. I think the value of a study like this is not just to highlight the benefit of frailty scores to help predict which patients may ultimately have a shorter survival, but also to help potentially guide which patients may be more suitable for intensive versus less intensive induction. I will note that this study was conducted in an era where we didn't have the same sorts of less intensive induction that are very effective in less fit patients, such as the combination of azacytidine and venetoclax, which is commonly used in less fit patients nowadays. So, the study may encompass patients who didn't have access to that therapy because it wasn't available during that time. But I think it still, overall, does highlight the fact that assessing fitness or frailty in acute myeloid leukemia is important for predictive value. Dr. John Sweetenham: I agree. Marc, I don't know what your thoughts are on this, but it goes either way. I mean, I think that, if I remember the numbers correctly, 25% of fit patients received non-intensive therapy. So, is there a missed opportunity there for that group of patients who actually may have tolerated the intensive therapy but it was never offered? Dr. Marc Braunstein: That's an excellent point, John, and I think that highlights the importance of frailty indices because they take into account much more than one particular factor, or even just a subjective assessment of the patient in real time when they're first presenting. And they may have disease-specific features that are decreasing, say one element of their assessment such as their performance status. So, really taking these composite fitness scores into account may actually allow you to escalate therapy in a patient who may actually be fit but maybe perceived as less fit when they present. Dr. John Sweetenham: Yeah. So, I think, as you mentioned, there are better treatment options out there now maybe than there were at the time this study was conducted. Nevertheless, there may still be that opportunity for more intensive therapy for some of these patients when they are more holistically assessed.  Let's move on and switch gears once again and talk about a study in multiple myeloma, the so-called IMROZ study, which is Abstract 7500. So, this is a study looking at treatment options for transplant-ineligible patients with newly diagnosed multiple myeloma. Some of these patients may not have a chance for subsequent therapy if they are not eligible for transplant. What are your thoughts on this study? Do you think we're closer to a new standard of care for patients who are not going to proceed to an autologous stem cell transplant?  Dr. Marc Braunstein: It seems like every year there's a new standard of care for newly diagnosed multiple myeloma because there's so much data emerging, which is just wonderful. So, I think as background, at the 2023 ASH meeting, the IsKia study was presented, which is a randomized phase 3 study in newly diagnosed transplant-eligible patients. And that was using isatuximab with carfilzomib, lenalidomide, and dexamethasone upfront and that study did show a benefit in terms of reducing minimal residual disease compared to carfilzomib, lenalidomide, and dexamethasone alone. But that study was looking at fit newly diagnosed patients who were going on to stem cell transplant. Right now, the standard of care for patients who are not eligible for transplant is generally to use a 2 or 3-drug regimen, such as daratumumab, lenalidomide, and dexamethasone, based on the phase 3 MAYA study. But this study is really unique in that it looks at using a quadruplet regimen in patients who are transplant ineligible or not intended to go for transplant.  So, the phase 3 IMROZ study was a randomized study of 446 patients that compared isatuximab, bortezomib, lenalidomide, and dexamethasone to bortezomib, lenalidomide, and dexamethasone alone. So, a quad versus a triplet regimen. The primary endpoint in this study was progression-free survival, but they also looked at secondary endpoints, such as complete response rate and minimal residual disease negativity.   Just to quickly highlight the results and then discuss the standard of care, the median duration of treatment in this study was 53 months in the quad regimen and 31 months in the control arm. At a median follow-up of about 60 months, the progression-free survival was not reached with the quad regimen versus 54 months in the triplet, and that was a significant difference. In addition, the safety profile was pretty much consistent with the class, there were a bit more grade three or higher treatment-emergent adverse events with the ESA-containing regimen, 92% versus 84%, but no difference in adverse events leading to discontinuation in either arm.   So, this study is certainly compelling in terms of using quadruplet-based regimens that contain an anti-CD38 monoclonal antibody for newly diagnosed patients who are not intended to undergo transplant. I think at the meeting, I will be interested to see the patient population that was included. Patients who are over the age of 80, for example, are excluded. So, I would like to know more about their fitness level and performance status. But I think it's clear, John, that using quad regimens over triplet regimens is just consistently superior in terms of efficacy outcomes. Dr. John Sweetenham: Right. I guess that, even though maybe we can't focus on the specific agents right now, it looks as if quad regimens are going to be the standard of care regimens for the future in this group. Do you think that is fair?  Dr. Marc Braunstein: Very likely. Dr. John Sweetenham: Absolutely. Well, that's a pretty challenging group of patients.   And so to move on again, let's talk about another, perhaps equally challenging group - patients with mantle cell lymphoma, particularly those who carry certain mutations. The so-called SYMPATICO study, which is reported in Abstract 7007, presents data on the efficacy and safety of ibrutinib and venetoclax in patients with mantle cell lymphoma who carry a TP53 mutation. We know that this mutation confers a high risk of early progressive disease and poorer outcomes when these patients are treated with standard chemoimmunotherapy for mantle cell. Trials to date have been limited to small single-arm studies. Can you tell us a little bit about this study and the outcomes and what you think it means for the future?  Dr. Marc Braunstein: As a background, although BTK inhibitors such as ibrutinib have yet to be approved for newly diagnosed mantle cell lymphoma, acalabrutinib and zanubrutinib, which are second-generation BTK inhibitors, are FDA-approved for previously treated mantle cell lymphoma. Ibrutinib was withdrawn from the market. The lead author of this abstract, Dr. Michael Wang, had presented a late-breaking data from the phase 3 SYMPATICO trial at ASH last year, in which 267 patients with relapsed or refractory mantle cell lymphoma after one to five prior lines of therapy were randomized to receive the combination of ibrutinib plus the BCL-2 inhibitor venetoclax or ibrutinib plus placebo. That study showed there was a 32 versus 22-month progression-free survival with a hazard ratio of 0.65 at a median follow-up of 51 months, indicating the PFS benefit of the combination of ibrutinib and venetoclax compared to ibrutinib with placebo.   So that leads us to this subgroup analysis in the current study being presented at ASCO, in which they looked at a subgroup of patients with mantle cell lymphoma who are at very high risk for treatment failure and early relapse - those are patients who have a mutation in TP53, which again is high risk for treatment failure. This abstract examined an open-label cohort of 44 first-line patients, as well as 75 patients who were in the relapse/refractory cohort, and compared to patients who either did or did not have the P53 mutation. When we look at the progression-free survival outcomes, the median progression-free survival in the first-line cohort of patients who did not have a P53 mutation was not reached, whereas those with the P53 mutation had a median progression-free survival of 22 months, which is still meaningful but still less than those who did not have a P53 mutation. Which again is not entirely unexpected. But the overall response rate of the combination of ibrutinib and venetoclax was very high at 90%, and the median duration of response was about 21 months.  Now comparing this to the relapse/refractory cohort, in those without a P53 mutation, the progression-free survival of the combination of ibrutinib and venetoclax was about 47 months versus those who don't have the P53 mutation was about 21 months with an overall response rate of 80%. I think one takeaway looking at this comparison of the first-line and relapse/refractory setting is that patients seem to do very similar in terms of overall response rate and progression-free survival, whether they were in the first line or in the later lines of treatment if they had the P53 mutation, which says that the combination of ibrutinib and venetoclax is effective no matter which phase of the disease the patient might be in, indicating its overall activity and being strong.    Dr. John Sweetenham: Yeah, I thought that was an interesting observation, actually, how similar the outcomes were in those two groups.  Dr. Marc Braunstein: No, I agree. And I think although patients with TP53 mutations did comparatively worse than those without the mutation according to progression-free survival, overall response rate, or complete remission rates, they did seem to be similar whether a patient was in first-line or relapsed refractory if they were P53 mutant and were treated with this combination. So, I think we need further data in the first line, such as the data that's awaiting publication from the TRIANGLE study, which is examining upfront ibrutinib. But certainly, BTK inhibitors have significant activity in either the first line or the relapse setting of mantle cell lymphoma.  Dr. John Sweetenham: Great. Thanks, Marc.  Let's wind up with one more abstract, and this is Abstract 7053. It's a 7-year analysis of the so-called ECHELON-1 study. This was a study comparing the standard of care, ABVD, with the same regimen with bleomycin substituted by brentuximab vedotin for patients with previously untreated advanced-stage classical Hodgkin lymphoma. The study at the time it was originally reported, resulted in a significant practice change in the first-line therapy of Hodgkin's lymphoma. We now have mature follow-up. What are your take-homes from this study? Dr. Marc Braunstein: The ECHELON-1 study has certainly been a practice-changing clinical trial where, as you said, brentuximab with the backbone of AVD was compared to ABVD, which was the prior standard. And this was examined in newly diagnosed patients with classical Hodgkin lymphoma who were at advanced-stage, stage 3 or 4. The publication, first of the progression-free survival, and more recently, in the New England Journal of Medicine in 2022, where we saw the 6-year overall survival was 94% with the brentuximab-containing arm versus 89% in the control arm, established the brentuximab AVD, or otherwise called AAVD, as the standard of care in advanced stage newly diagnosed classical Hodgkin lymphoma. The current study is now reporting 7-year follow-up on about 1,300 randomized patients who were enrolled in this impressive study.   Though at a median follow-up of 89 months now, the 7-year overall survival was quite similar, 94% versus 89%, again favoring the brentuximab-containing arm. In particular, this was driven by patients who had stage 4 disease or those patients who were aged less than 60 in subgroup analyses. So, what I take away from this abstract in the 7-year follow-up of the ECHELON-1 is that brentuximab with AVD remains the standard of care for previously untreated advanced-stage classical Hodgkin lymphoma. It is worth noting that the SWOG S1826 study that was presented at ASCO last year compared nivolumab with AVD compared to brentuximab AVD and did show a slight PFS advantage of 94% versus 86% with nivolumab AVD. Obviously, these were different studies with different patient populations enrolled, so we're really just cross-comparing different studies. But I think brentuximab AVD, given the survival benefit that is retained now at seven years in the current abstract, still remains the standard of care for advanced-stage classical Hodgkin lymphoma. The role of immune checkpoint inhibitors like nivolumab is making headway in terms of treating newly diagnosed patients as well. Dr. John Sweetenham: Yeah, thanks, Marc. I mean, one of the observations that I thought was of interest in this study was the outcome for patients who were PET-2 positive, when you compare AAVD and ABVD. It does seem as if even in those patients who are PET-2 positive, having had AAVD, they still apparently have a better outcome than those who received ABVD in that situation who were PET-2 positive. So, I think that's another interesting observation. I'm not quite sure what it means, except speaking to the overall superior efficacy of that regimen. Dr. Marc Braunstein: You make a great point, John, because it's worth noting that in ECHELON-1, a PET scan was done after cycle 2, but the study was not PET-adapted. So even if you had a positive PET, you continued for the full six cycles of treatment. But PET-2 status is often used in various studies of Hodgkin lymphoma to guide whether to give additional cycles or escalate therapy. So, I think the benefit of presenting those subgroups is that even if you were PET-2 positive, you still did better by continuing on the brentuximab-containing regimen. Dr. John Sweetenham: Yeah, exactly. I mean, the other important takeaway message, I think, is that the outcome for patients with advanced Hodgkin lymphoma seems to continue to steadily improve, which is great news and also really remarkable. And I'm excited to see there may be some additional data presented at one of the late-breaking abstracts in this year's meeting, so it will truly be interesting to see what that shows us as well.  Dr. Marc Braunstein: Incredible. Dr. John Sweetenham: Well, Marc, as always, thank you for sharing your insights with us today on the ASCO Daily News Podcast. We look forward very much to hearing the updated data from these abstracts at the meeting.  Dr. Marc Braunstein: As do I and thank you so much for inviting me again.  Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's guest: Dr. Marc Braunstein @docbraunstein   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Facebook  ASCO on LinkedIn    Disclosures:  Dr. John Sweetenham: Consulting or Advisory Role: EMA Wellness   Dr. Marc Braunstein: Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb/Celgene, Adaptive Biotechnologies, GlaxoSmithKline, ADC Therapeutics, Janssen Oncology, Abbvie, Guidepoint Global, Epizyme, Sanofi, CTI BioPharma Corp Speakers' Bureau: Janssen Oncology Research Funding (Institution): Janssen, Celgene/BMS

Keith Fairall, PharmD. MBA, National MSL Director at Adaptive Biotechnologies discusses the diagnostic MSL role. Learn more about…

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/EJG865. CME/NCPD credit will be available until March 20, 2025.Canceling the Cascade of VOD/SOS: Team-Based Prophylaxis, Diagnosis, and Customized ManagementThe Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.DisclosuresProf. Mohamad Mohty, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Adaptive Biotechnologies; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; Stemline Therapeutics, Inc.; and Takeda Pharmaceutical Company.Honoraria from Adaptive Biotechnologies; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; Stemline Therapeutics, Inc.; and Takeda Pharmaceutical Company.Christine N. Duncan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for bluebird bio, Inc.; Jazz Pharmaceuticals, Inc.; and Omeros Corporation.Medical DirectorCarmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/EJG865. CME/NCPD credit will be available until March 20, 2025.Canceling the Cascade of VOD/SOS: Team-Based Prophylaxis, Diagnosis, and Customized ManagementThe Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.DisclosuresProf. Mohamad Mohty, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Adaptive Biotechnologies; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; Stemline Therapeutics, Inc.; and Takeda Pharmaceutical Company.Honoraria from Adaptive Biotechnologies; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; Stemline Therapeutics, Inc.; and Takeda Pharmaceutical Company.Christine N. Duncan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for bluebird bio, Inc.; Jazz Pharmaceuticals, Inc.; and Omeros Corporation.Medical DirectorCarmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/EJG865. CME/NCPD credit will be available until March 20, 2025.Canceling the Cascade of VOD/SOS: Team-Based Prophylaxis, Diagnosis, and Customized ManagementThe Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.DisclosuresProf. Mohamad Mohty, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Adaptive Biotechnologies; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; Stemline Therapeutics, Inc.; and Takeda Pharmaceutical Company.Honoraria from Adaptive Biotechnologies; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; Stemline Therapeutics, Inc.; and Takeda Pharmaceutical Company.Christine N. Duncan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for bluebird bio, Inc.; Jazz Pharmaceuticals, Inc.; and Omeros Corporation.Medical DirectorCarmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/EJG865. CME/NCPD credit will be available until March 20, 2025.Canceling the Cascade of VOD/SOS: Team-Based Prophylaxis, Diagnosis, and Customized ManagementThe Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.DisclosuresProf. Mohamad Mohty, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Adaptive Biotechnologies; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; Stemline Therapeutics, Inc.; and Takeda Pharmaceutical Company.Honoraria from Adaptive Biotechnologies; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; Stemline Therapeutics, Inc.; and Takeda Pharmaceutical Company.Christine N. Duncan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for bluebird bio, Inc.; Jazz Pharmaceuticals, Inc.; and Omeros Corporation.Medical DirectorCarmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/EJG865. CME/NCPD credit will be available until March 20, 2025.Canceling the Cascade of VOD/SOS: Team-Based Prophylaxis, Diagnosis, and Customized ManagementThe Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.DisclosuresProf. Mohamad Mohty, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Adaptive Biotechnologies; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; Stemline Therapeutics, Inc.; and Takeda Pharmaceutical Company.Honoraria from Adaptive Biotechnologies; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; Stemline Therapeutics, Inc.; and Takeda Pharmaceutical Company.Christine N. Duncan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for bluebird bio, Inc.; Jazz Pharmaceuticals, Inc.; and Omeros Corporation.Medical DirectorCarmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/EJG865. CME/NCPD credit will be available until March 20, 2025.Canceling the Cascade of VOD/SOS: Team-Based Prophylaxis, Diagnosis, and Customized ManagementThe Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.DisclosuresProf. Mohamad Mohty, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Adaptive Biotechnologies; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; Stemline Therapeutics, Inc.; and Takeda Pharmaceutical Company.Honoraria from Adaptive Biotechnologies; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; Stemline Therapeutics, Inc.; and Takeda Pharmaceutical Company.Christine N. Duncan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for bluebird bio, Inc.; Jazz Pharmaceuticals, Inc.; and Omeros Corporation.Medical DirectorCarmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/EJG865. CME/NCPD credit will be available until March 20, 2025.Canceling the Cascade of VOD/SOS: Team-Based Prophylaxis, Diagnosis, and Customized ManagementThe Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.DisclosuresProf. Mohamad Mohty, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Adaptive Biotechnologies; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; Stemline Therapeutics, Inc.; and Takeda Pharmaceutical Company.Honoraria from Adaptive Biotechnologies; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; Stemline Therapeutics, Inc.; and Takeda Pharmaceutical Company.Christine N. Duncan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for bluebird bio, Inc.; Jazz Pharmaceuticals, Inc.; and Omeros Corporation.Medical DirectorCarmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/EJG865. CME/NCPD credit will be available until March 20, 2025.Canceling the Cascade of VOD/SOS: Team-Based Prophylaxis, Diagnosis, and Customized ManagementThe Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.DisclosuresProf. Mohamad Mohty, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Adaptive Biotechnologies; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; Stemline Therapeutics, Inc.; and Takeda Pharmaceutical Company.Honoraria from Adaptive Biotechnologies; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; Stemline Therapeutics, Inc.; and Takeda Pharmaceutical Company.Christine N. Duncan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for bluebird bio, Inc.; Jazz Pharmaceuticals, Inc.; and Omeros Corporation.Medical DirectorCarmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YUZ865. CME/MOC credit will be available until December 31, 2024.Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential ManagementPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and CLL Society.SupportThis activity is supported by independent educational grants from AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.DisclosuresProf. John G. Gribben, MD, DSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen and Gilead Sciences/Kite.Grant/Research Support from AstraZeneca.John N. Allan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene, Inc.; Epizyme, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; LAVA Therapeutics; Lilly; Pharmacyclics LLC; and TG Therapeutics, Inc.Grant/Research Support from BeiGene, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Speaker for AbbVie; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology, Inc.; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.Honoraria from Brazilian Association of Hematology; Curio Science; Dava Oncology; Hemotherapy and Cellular Therapy (ABHH); Intellisphere LLC; Massachusetts Medical Society; MJH Life Sciences; Phillips Group Oncology Communications; and VJHemOnc.Larry Marion has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YUZ865. CME/MOC credit will be available until December 31, 2024.Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential ManagementPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and CLL Society.SupportThis activity is supported by independent educational grants from AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.DisclosuresProf. John G. Gribben, MD, DSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen and Gilead Sciences/Kite.Grant/Research Support from AstraZeneca.John N. Allan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene, Inc.; Epizyme, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; LAVA Therapeutics; Lilly; Pharmacyclics LLC; and TG Therapeutics, Inc.Grant/Research Support from BeiGene, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Speaker for AbbVie; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology, Inc.; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.Honoraria from Brazilian Association of Hematology; Curio Science; Dava Oncology; Hemotherapy and Cellular Therapy (ABHH); Intellisphere LLC; Massachusetts Medical Society; MJH Life Sciences; Phillips Group Oncology Communications; and VJHemOnc.Larry Marion has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YUZ865. CME/MOC credit will be available until December 31, 2024.Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential ManagementPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and CLL Society.SupportThis activity is supported by independent educational grants from AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.DisclosuresProf. John G. Gribben, MD, DSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen and Gilead Sciences/Kite.Grant/Research Support from AstraZeneca.John N. Allan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene, Inc.; Epizyme, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; LAVA Therapeutics; Lilly; Pharmacyclics LLC; and TG Therapeutics, Inc.Grant/Research Support from BeiGene, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Speaker for AbbVie; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology, Inc.; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.Honoraria from Brazilian Association of Hematology; Curio Science; Dava Oncology; Hemotherapy and Cellular Therapy (ABHH); Intellisphere LLC; Massachusetts Medical Society; MJH Life Sciences; Phillips Group Oncology Communications; and VJHemOnc.Larry Marion has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YUZ865. CME/MOC credit will be available until December 31, 2024.Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential ManagementPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and CLL Society.SupportThis activity is supported by independent educational grants from AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.DisclosuresProf. John G. Gribben, MD, DSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen and Gilead Sciences/Kite.Grant/Research Support from AstraZeneca.John N. Allan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene, Inc.; Epizyme, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; LAVA Therapeutics; Lilly; Pharmacyclics LLC; and TG Therapeutics, Inc.Grant/Research Support from BeiGene, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Speaker for AbbVie; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology, Inc.; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.Honoraria from Brazilian Association of Hematology; Curio Science; Dava Oncology; Hemotherapy and Cellular Therapy (ABHH); Intellisphere LLC; Massachusetts Medical Society; MJH Life Sciences; Phillips Group Oncology Communications; and VJHemOnc.Larry Marion has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YUZ865. CME/MOC credit will be available until December 31, 2024.Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential ManagementPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and CLL Society.SupportThis activity is supported by independent educational grants from AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.DisclosuresProf. John G. Gribben, MD, DSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen and Gilead Sciences/Kite.Grant/Research Support from AstraZeneca.John N. Allan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene, Inc.; Epizyme, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; LAVA Therapeutics; Lilly; Pharmacyclics LLC; and TG Therapeutics, Inc.Grant/Research Support from BeiGene, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Speaker for AbbVie; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology, Inc.; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.Honoraria from Brazilian Association of Hematology; Curio Science; Dava Oncology; Hemotherapy and Cellular Therapy (ABHH); Intellisphere LLC; Massachusetts Medical Society; MJH Life Sciences; Phillips Group Oncology Communications; and VJHemOnc.Larry Marion has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YUZ865. CME/MOC credit will be available until December 31, 2024.Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential ManagementPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and CLL Society.SupportThis activity is supported by independent educational grants from AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.DisclosuresProf. John G. Gribben, MD, DSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen and Gilead Sciences/Kite.Grant/Research Support from AstraZeneca.John N. Allan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene, Inc.; Epizyme, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; LAVA Therapeutics; Lilly; Pharmacyclics LLC; and TG Therapeutics, Inc.Grant/Research Support from BeiGene, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Speaker for AbbVie; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology, Inc.; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.Honoraria from Brazilian Association of Hematology; Curio Science; Dava Oncology; Hemotherapy and Cellular Therapy (ABHH); Intellisphere LLC; Massachusetts Medical Society; MJH Life Sciences; Phillips Group Oncology Communications; and VJHemOnc.Larry Marion has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MGG865. CME/MOC/AAPA credit will be available until December 31, 2024.Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNikhil C. Munshi, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Amgen Inc; Bristol Myers Squibb; Celgene Corporation; DCT Pfizer; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Legend Biotech; Novartis Pharmaceuticals Corporation; OncoPep, Inc.; and Takeda Pharmaceutical Company Limited.Other Financial or Material Support from OncoPep, Inc. for patents and royalties. He is a current equity holder and a scientific founder for OncoPep, Inc.Faculty/PlannerHans Lee, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allogene Therapeutics; Bristol Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer; Regeneron Pharmaceuticals, Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen; Bristol Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerProf. Mohamad Mohty has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Grant/Research Support from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Speaker for Jazz Pharmaceuticals, Inc.Honoraria from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Faculty/PlannerKrina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and Precision BioSciences, Inc.Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MGG865. CME/MOC/AAPA credit will be available until December 31, 2024.Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNikhil C. Munshi, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Amgen Inc; Bristol Myers Squibb; Celgene Corporation; DCT Pfizer; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Legend Biotech; Novartis Pharmaceuticals Corporation; OncoPep, Inc.; and Takeda Pharmaceutical Company Limited.Other Financial or Material Support from OncoPep, Inc. for patents and royalties. He is a current equity holder and a scientific founder for OncoPep, Inc.Faculty/PlannerHans Lee, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allogene Therapeutics; Bristol Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer; Regeneron Pharmaceuticals, Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen; Bristol Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerProf. Mohamad Mohty has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Grant/Research Support from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Speaker for Jazz Pharmaceuticals, Inc.Honoraria from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Faculty/PlannerKrina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and Precision BioSciences, Inc.Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MGG865. CME/MOC/AAPA credit will be available until December 31, 2024.Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNikhil C. Munshi, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Amgen Inc; Bristol Myers Squibb; Celgene Corporation; DCT Pfizer; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Legend Biotech; Novartis Pharmaceuticals Corporation; OncoPep, Inc.; and Takeda Pharmaceutical Company Limited.Other Financial or Material Support from OncoPep, Inc. for patents and royalties. He is a current equity holder and a scientific founder for OncoPep, Inc.Faculty/PlannerHans Lee, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allogene Therapeutics; Bristol Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer; Regeneron Pharmaceuticals, Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen; Bristol Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerProf. Mohamad Mohty has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Grant/Research Support from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Speaker for Jazz Pharmaceuticals, Inc.Honoraria from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Faculty/PlannerKrina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and Precision BioSciences, Inc.Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MGG865. CME/MOC/AAPA credit will be available until December 31, 2024.Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNikhil C. Munshi, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Amgen Inc; Bristol Myers Squibb; Celgene Corporation; DCT Pfizer; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Legend Biotech; Novartis Pharmaceuticals Corporation; OncoPep, Inc.; and Takeda Pharmaceutical Company Limited.Other Financial or Material Support from OncoPep, Inc. for patents and royalties. He is a current equity holder and a scientific founder for OncoPep, Inc.Faculty/PlannerHans Lee, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allogene Therapeutics; Bristol Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer; Regeneron Pharmaceuticals, Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen; Bristol Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerProf. Mohamad Mohty has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Grant/Research Support from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Speaker for Jazz Pharmaceuticals, Inc.Honoraria from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Faculty/PlannerKrina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and Precision BioSciences, Inc.Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MGG865. CME/MOC/AAPA credit will be available until December 31, 2024.Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNikhil C. Munshi, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Amgen Inc; Bristol Myers Squibb; Celgene Corporation; DCT Pfizer; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Legend Biotech; Novartis Pharmaceuticals Corporation; OncoPep, Inc.; and Takeda Pharmaceutical Company Limited.Other Financial or Material Support from OncoPep, Inc. for patents and royalties. He is a current equity holder and a scientific founder for OncoPep, Inc.Faculty/PlannerHans Lee, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allogene Therapeutics; Bristol Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer; Regeneron Pharmaceuticals, Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen; Bristol Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerProf. Mohamad Mohty has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Grant/Research Support from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Speaker for Jazz Pharmaceuticals, Inc.Honoraria from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Faculty/PlannerKrina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and Precision BioSciences, Inc.Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MGG865. CME/MOC/AAPA credit will be available until December 31, 2024.Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNikhil C. Munshi, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Amgen Inc; Bristol Myers Squibb; Celgene Corporation; DCT Pfizer; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Legend Biotech; Novartis Pharmaceuticals Corporation; OncoPep, Inc.; and Takeda Pharmaceutical Company Limited.Other Financial or Material Support from OncoPep, Inc. for patents and royalties. He is a current equity holder and a scientific founder for OncoPep, Inc.Faculty/PlannerHans Lee, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allogene Therapeutics; Bristol Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer; Regeneron Pharmaceuticals, Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen; Bristol Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerProf. Mohamad Mohty has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Grant/Research Support from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Speaker for Jazz Pharmaceuticals, Inc.Honoraria from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Faculty/PlannerKrina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and Precision BioSciences, Inc.Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/BFU865. CME/MOC/AAPA credit will be available until November 7, 2024.Choosing Wisely, Achieving Control With BTKi in CLL: Perspectives on Safety-Informed Approaches to Enhanced Therapeutic Efficacy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJohn C. Byrd, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Eilean Therapeutics; Janssen Pharmaceuticals, Inc.; Kura Oncology, Inc.; Newave Pharmaceutical Inc; Novartis Pharmaceuticals Corporation; Orange Grove Bio; Syndax; Trillium Therapeutics; and Vincerx Pharma.Grant/Research Support from Eilean Therapeutics; Newave Pharmaceutical Inc; and OrbiMed.Stock Shareholder in Eilean Therapeutics; Kura Oncology, Inc.; and Vincerx Pharma.Other Financial or Material Support in the form of patents for Ohio State University.Faculty/PlannerDaniel Addison, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from American Heart Association-Robert Wood Johnson Foundation and National Institutes of Health (NIH) grants: K23-HL155890 and R01HL170038.Faculty/PlannerMatthew S. Davids, MD, MMSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Genentech, Inc.; Genmab; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mingsight Pharmaceuticals Inc.; Secura Bio; Takeda Pharmaceutical Company Ltd.; and TG Therapeutics, Inc.Grant/Research Support from AbbVie; Ascentage Pharma; AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Secura Bio; and TG Therapeutics, Inc.Honoraria from Aptitude Health; Bio Ascend; and Curio Science.Other Financial or Material Support in the form of Royalties from Up-to-Date.Faculty/PlannerJennifer Woyach, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave Pharmaceutical Inc; and Pharmacyclics LLC.Grant/Research Support from AstraZeneca; Karyopharm Therapeutics; Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.; Schrödinger, Inc.; and Verastem Oncology.Faculty/PlannerPaolo Ghia, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; BeiGene, Inc./Merck Sharp & Dohme; Bristol Myers Squibb; and F. Hoffmann-La Roche Ltd.Grant/Research Support from Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; and Bristol Myers Squibb.Speaker for AstraZeneca/Janssen Pharmaceuticals, Inc. and BeiGene, Inc./Merck Sharp & Dohme.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/BFU865. CME/MOC/AAPA credit will be available until November 7, 2024.Choosing Wisely, Achieving Control With BTKi in CLL: Perspectives on Safety-Informed Approaches to Enhanced Therapeutic Efficacy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJohn C. Byrd, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Eilean Therapeutics; Janssen Pharmaceuticals, Inc.; Kura Oncology, Inc.; Newave Pharmaceutical Inc; Novartis Pharmaceuticals Corporation; Orange Grove Bio; Syndax; Trillium Therapeutics; and Vincerx Pharma.Grant/Research Support from Eilean Therapeutics; Newave Pharmaceutical Inc; and OrbiMed.Stock Shareholder in Eilean Therapeutics; Kura Oncology, Inc.; and Vincerx Pharma.Other Financial or Material Support in the form of patents for Ohio State University.Faculty/PlannerDaniel Addison, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from American Heart Association-Robert Wood Johnson Foundation and National Institutes of Health (NIH) grants: K23-HL155890 and R01HL170038.Faculty/PlannerMatthew S. Davids, MD, MMSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Genentech, Inc.; Genmab; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mingsight Pharmaceuticals Inc.; Secura Bio; Takeda Pharmaceutical Company Ltd.; and TG Therapeutics, Inc.Grant/Research Support from AbbVie; Ascentage Pharma; AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Secura Bio; and TG Therapeutics, Inc.Honoraria from Aptitude Health; Bio Ascend; and Curio Science.Other Financial or Material Support in the form of Royalties from Up-to-Date.Faculty/PlannerJennifer Woyach, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave Pharmaceutical Inc; and Pharmacyclics LLC.Grant/Research Support from AstraZeneca; Karyopharm Therapeutics; Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.; Schrödinger, Inc.; and Verastem Oncology.Faculty/PlannerPaolo Ghia, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; BeiGene, Inc./Merck Sharp & Dohme; Bristol Myers Squibb; and F. Hoffmann-La Roche Ltd.Grant/Research Support from Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; and Bristol Myers Squibb.Speaker for AstraZeneca/Janssen Pharmaceuticals, Inc. and BeiGene, Inc./Merck Sharp & Dohme.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/BFU865. CME/MOC/AAPA credit will be available until November 7, 2024.Choosing Wisely, Achieving Control With BTKi in CLL: Perspectives on Safety-Informed Approaches to Enhanced Therapeutic Efficacy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJohn C. Byrd, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Eilean Therapeutics; Janssen Pharmaceuticals, Inc.; Kura Oncology, Inc.; Newave Pharmaceutical Inc; Novartis Pharmaceuticals Corporation; Orange Grove Bio; Syndax; Trillium Therapeutics; and Vincerx Pharma.Grant/Research Support from Eilean Therapeutics; Newave Pharmaceutical Inc; and OrbiMed.Stock Shareholder in Eilean Therapeutics; Kura Oncology, Inc.; and Vincerx Pharma.Other Financial or Material Support in the form of patents for Ohio State University.Faculty/PlannerDaniel Addison, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from American Heart Association-Robert Wood Johnson Foundation and National Institutes of Health (NIH) grants: K23-HL155890 and R01HL170038.Faculty/PlannerMatthew S. Davids, MD, MMSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Genentech, Inc.; Genmab; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mingsight Pharmaceuticals Inc.; Secura Bio; Takeda Pharmaceutical Company Ltd.; and TG Therapeutics, Inc.Grant/Research Support from AbbVie; Ascentage Pharma; AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Secura Bio; and TG Therapeutics, Inc.Honoraria from Aptitude Health; Bio Ascend; and Curio Science.Other Financial or Material Support in the form of Royalties from Up-to-Date.Faculty/PlannerJennifer Woyach, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave Pharmaceutical Inc; and Pharmacyclics LLC.Grant/Research Support from AstraZeneca; Karyopharm Therapeutics; Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.; Schrödinger, Inc.; and Verastem Oncology.Faculty/PlannerPaolo Ghia, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; BeiGene, Inc./Merck Sharp & Dohme; Bristol Myers Squibb; and F. Hoffmann-La Roche Ltd.Grant/Research Support from Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; and Bristol Myers Squibb.Speaker for AstraZeneca/Janssen Pharmaceuticals, Inc. and BeiGene, Inc./Merck Sharp & Dohme.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/BFU865. CME/MOC/AAPA credit will be available until November 7, 2024.Choosing Wisely, Achieving Control With BTKi in CLL: Perspectives on Safety-Informed Approaches to Enhanced Therapeutic Efficacy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJohn C. Byrd, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Eilean Therapeutics; Janssen Pharmaceuticals, Inc.; Kura Oncology, Inc.; Newave Pharmaceutical Inc; Novartis Pharmaceuticals Corporation; Orange Grove Bio; Syndax; Trillium Therapeutics; and Vincerx Pharma.Grant/Research Support from Eilean Therapeutics; Newave Pharmaceutical Inc; and OrbiMed.Stock Shareholder in Eilean Therapeutics; Kura Oncology, Inc.; and Vincerx Pharma.Other Financial or Material Support in the form of patents for Ohio State University.Faculty/PlannerDaniel Addison, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from American Heart Association-Robert Wood Johnson Foundation and National Institutes of Health (NIH) grants: K23-HL155890 and R01HL170038.Faculty/PlannerMatthew S. Davids, MD, MMSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Genentech, Inc.; Genmab; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mingsight Pharmaceuticals Inc.; Secura Bio; Takeda Pharmaceutical Company Ltd.; and TG Therapeutics, Inc.Grant/Research Support from AbbVie; Ascentage Pharma; AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Secura Bio; and TG Therapeutics, Inc.Honoraria from Aptitude Health; Bio Ascend; and Curio Science.Other Financial or Material Support in the form of Royalties from Up-to-Date.Faculty/PlannerJennifer Woyach, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave Pharmaceutical Inc; and Pharmacyclics LLC.Grant/Research Support from AstraZeneca; Karyopharm Therapeutics; Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.; Schrödinger, Inc.; and Verastem Oncology.Faculty/PlannerPaolo Ghia, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; BeiGene, Inc./Merck Sharp & Dohme; Bristol Myers Squibb; and F. Hoffmann-La Roche Ltd.Grant/Research Support from Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; and Bristol Myers Squibb.Speaker for AstraZeneca/Janssen Pharmaceuticals, Inc. and BeiGene, Inc./Merck Sharp & Dohme.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/BFU865. CME/MOC/AAPA credit will be available until November 7, 2024.Choosing Wisely, Achieving Control With BTKi in CLL: Perspectives on Safety-Informed Approaches to Enhanced Therapeutic Efficacy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJohn C. Byrd, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Eilean Therapeutics; Janssen Pharmaceuticals, Inc.; Kura Oncology, Inc.; Newave Pharmaceutical Inc; Novartis Pharmaceuticals Corporation; Orange Grove Bio; Syndax; Trillium Therapeutics; and Vincerx Pharma.Grant/Research Support from Eilean Therapeutics; Newave Pharmaceutical Inc; and OrbiMed.Stock Shareholder in Eilean Therapeutics; Kura Oncology, Inc.; and Vincerx Pharma.Other Financial or Material Support in the form of patents for Ohio State University.Faculty/PlannerDaniel Addison, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from American Heart Association-Robert Wood Johnson Foundation and National Institutes of Health (NIH) grants: K23-HL155890 and R01HL170038.Faculty/PlannerMatthew S. Davids, MD, MMSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Genentech, Inc.; Genmab; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mingsight Pharmaceuticals Inc.; Secura Bio; Takeda Pharmaceutical Company Ltd.; and TG Therapeutics, Inc.Grant/Research Support from AbbVie; Ascentage Pharma; AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Secura Bio; and TG Therapeutics, Inc.Honoraria from Aptitude Health; Bio Ascend; and Curio Science.Other Financial or Material Support in the form of Royalties from Up-to-Date.Faculty/PlannerJennifer Woyach, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave Pharmaceutical Inc; and Pharmacyclics LLC.Grant/Research Support from AstraZeneca; Karyopharm Therapeutics; Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.; Schrödinger, Inc.; and Verastem Oncology.Faculty/PlannerPaolo Ghia, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; BeiGene, Inc./Merck Sharp & Dohme; Bristol Myers Squibb; and F. Hoffmann-La Roche Ltd.Grant/Research Support from Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; and Bristol Myers Squibb.Speaker for AstraZeneca/Janssen Pharmaceuticals, Inc. and BeiGene, Inc./Merck Sharp & Dohme.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/BFU865. CME/MOC/AAPA credit will be available until November 7, 2024.Choosing Wisely, Achieving Control With BTKi in CLL: Perspectives on Safety-Informed Approaches to Enhanced Therapeutic Efficacy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJohn C. Byrd, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Eilean Therapeutics; Janssen Pharmaceuticals, Inc.; Kura Oncology, Inc.; Newave Pharmaceutical Inc; Novartis Pharmaceuticals Corporation; Orange Grove Bio; Syndax; Trillium Therapeutics; and Vincerx Pharma.Grant/Research Support from Eilean Therapeutics; Newave Pharmaceutical Inc; and OrbiMed.Stock Shareholder in Eilean Therapeutics; Kura Oncology, Inc.; and Vincerx Pharma.Other Financial or Material Support in the form of patents for Ohio State University.Faculty/PlannerDaniel Addison, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from American Heart Association-Robert Wood Johnson Foundation and National Institutes of Health (NIH) grants: K23-HL155890 and R01HL170038.Faculty/PlannerMatthew S. Davids, MD, MMSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Genentech, Inc.; Genmab; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mingsight Pharmaceuticals Inc.; Secura Bio; Takeda Pharmaceutical Company Ltd.; and TG Therapeutics, Inc.Grant/Research Support from AbbVie; Ascentage Pharma; AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Secura Bio; and TG Therapeutics, Inc.Honoraria from Aptitude Health; Bio Ascend; and Curio Science.Other Financial or Material Support in the form of Royalties from Up-to-Date.Faculty/PlannerJennifer Woyach, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave Pharmaceutical Inc; and Pharmacyclics LLC.Grant/Research Support from AstraZeneca; Karyopharm Therapeutics; Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.; Schrödinger, Inc.; and Verastem Oncology.Faculty/PlannerPaolo Ghia, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; BeiGene, Inc./Merck Sharp & Dohme; Bristol Myers Squibb; and F. Hoffmann-La Roche Ltd.Grant/Research Support from Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; and Bristol Myers Squibb.Speaker for AstraZeneca/Janssen Pharmaceuticals, Inc. and BeiGene, Inc./Merck Sharp & Dohme.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below

Adaptive Biotechnologies Corporation, Q2 2023 Earnings Call, Aug 02, 2023

Allison Jacob, Senior Medical Director at Adaptive Biotechnologies, uses their technology to decode the genetic language of the immune system and develop clinical diagnostics and therapeutics for hematologic malignancies. With a focus on the adaptive immune system and the receptors of B and T cells, the platform is used to identify, monitor and precisely quantify tumor cells over time. In the past, MRD stood for minimal residual disease, but due to more accurate testing, the goal now is measurable residual disease, MRD, negativity. Allison explains, "The clonoSEQ technology essentially looks at rearrangements in the DNA of proteins that are expressed on B cells, and we're harnessing something that the immune system created for us. So, unlike other genes that we talk about in cancer, let's say like BRCA1, where you have a normal version of that and a mutated version of that, B-cell receptors are constantly having to shuffle and create new gDNA sequences, again, to be able to recognize these foreign invaders." "What that means is that within this very small region of DNA, let's say 150 to 200 base pairs, there's a diversity upwards of 10-12. So, when we talk about clonoSEQ as a clinical diagnostic, what that means is that these sequences are unique and are expressed by that tumor cell and its progeny and can be used essentially as a barcode to track and quantify that tumor over time." "I think one of the most important aspects we spoke to a little bit ago is having a deeper understanding of how and if the patient is responding to therapy. So even if a patient is in a complete response, we know that if they're MRD positive, they have a higher likelihood of relapse. So, identifying patients with the best prognosis, complete response, and MRD negative can be very helpful in understanding what's coming." #AdaptiveBiotechnologies #PrecisionDiagnostics #PatientEmpowerment #MRD #Myeloma #clonoSEQ #Immunosequencing  AdaptiveBiotech.com  Download the transcript here

Allison Jacob, Senior Medical Director at Adaptive Biotechnologies, uses their technology to decode the genetic language of the immune system and develop clinical diagnostics and therapeutics for hematologic malignancies. With a focus on the adaptive immune system and the receptors of B and T cells, the platform is used to identify, monitor and precisely quantify tumor cells over time. In the past, MRD stood for minimal residual disease, but due to more accurate testing, the goal now is measurable residual disease, MRD, negativity. Allison explains, "The clonoSEQ technology essentially looks at rearrangements in the DNA of proteins that are expressed on B cells, and we're harnessing something that the immune system created for us. So, unlike other genes that we talk about in cancer, let's say like BRCA1, where you have a normal version of that and a mutated version of that, B-cell receptors are constantly having to shuffle and create new gDNA sequences, again, to be able to recognize these foreign invaders." "What that means is that within this very small region of DNA, let's say 150 to 200 base pairs, there's a diversity upwards of 10-12. So, when we talk about clonoSEQ as a clinical diagnostic, what that means is that these sequences are unique and are expressed by that tumor cell and its progeny and can be used essentially as a barcode to track and quantify that tumor over time." "I think one of the most important aspects we spoke to a little bit ago is having a deeper understanding of how and if the patient is responding to therapy. So even if a patient is in a complete response, we know that if they're MRD positive, they have a higher likelihood of relapse. So, identifying patients with the best prognosis, complete response, and MRD negative can be very helpful in understanding what's coming." #AdaptiveBiotechnologies #PrecisionDiagnostics #PatientEmpowerment #MRD #Myeloma #clonoSEQ #Immunosequencing  AdaptiveBiotech.com  Listen to the podcast here

Drs. John Sweetenham and Marc Braunstein discuss advances in hematologic malignancies featured at the 2023 ASCO Annual Meeting, including the potentially practice-changing SWOG-S1826 study in Hodgkin lymphoma, the promise of bispecific antibodies in B-cell malignancies, and a novel approach to deliver vital anti-myeloma medications that could improve patient quality of life and alleviate barriers to care. TRANSCRIPT   Dr. John Sweetenham: Hello, I'm John Sweetenham, the associate director for cancer network clinical affairs at UT Southwestern's Harold C. Simmons Comprehensive Cancer Center and the host of the ASCO Daily News Podcast.    The 2023 ASCO Annual Meeting featured some exciting new data on hematologic malignancies. I'm delighted to have Dr. Marc Braunstein return to the podcast to discuss some of these potentially practice-changing studies and new approaches in the heme space. Dr. Braunstein is a hematologist and oncologist at the NYU Perlmutter Cancer Center.    You'll find our full disclosures in the transcript of this episode, and disclosures of all guests on the ASCO Daily News Podcast are available on our transcripts at asco.org/DNpod.   Marc, it's great to have you back on the podcast, and thanks for being here again.   Dr. Marc Braunstein: Thank you, John. It's great to be back.   Dr. John Sweetenham: Marc, we already mentioned that there are some potentially practice-changing studies that were reported at ASCO this year. And among those, LBA4, which was presented in the Plenary Session, was a study which explored the treatment of advanced Hodgkin lymphoma. This was the Southwest Oncology Group study S1826. Could you give us your insights on this?    Dr. Marc Braunstein: Sure, happy to discuss S1826. So as background, you know, the ECHELON-1 study, which was published in the New England Journal of Medicine in 2022 showed a 40% decrease in the risk of death at six years follow-up by adding brentuximab to AVD compared to bleomycin AVD. And that was in high risk or advanced-stage patients and that led to adoption of brentuximab for upfront use in patients with classical Hodgkin lymphoma in advanced stage.    Also of note, immune checkpoint inhibitors such as pembrolizumab or nivolumab do have activity in the relapse setting. The SWOG S1826 study was a randomized control study looking at the use of the PD-1 inhibitor nivolumab plus AVD versus brentuximab AVD in patients with advanced stage classical Hodgkin lymphoma who are at least twelve years of age. And the primary endpoint in the study was progression-free survival.     It was a large study which enrolled 976 patients and randomized them one to one to either nivo AVD or brentuximab AVD. The median age in the study was 27 and the median follow-up was 12 months. And what the study found, which could be practice-changing, was that the primary endpoint of progression-free survival was superior in the nivolumab arm with a hazard ratio of 0.8 and a one-year PFS of 94% versus 86%, favoring the nivolumab arm. And while there were side effects associated with the class of medications, for example, hypo or hyperthyroidism was more frequent in the nivolumab group, whereas peripheral neuropathy was higher in the brentuximab group, I think that these results are particularly encouraging for how we can continue to improve outcomes for patients with advanced-stage classical Hodgkin lymphoma. And this may be practice-changing in terms of whether we use upfront immune checkpoint inhibitors in combination with our standard chemotherapy backbone.    Dr. John Sweetenham: Yeah, absolutely. There are a couple of things that occur to me. One in particular which is unique about this study, and the fact that it was for patients who are 12 years and older in many respects represents a first because I can't think of another large, randomized study of this type which has attempted to align pediatric and adult care of patients with Hodgkin lymphoma. So, I think it's something of a landmark in that regard. I don't know if you'd agree with that.    Dr. Marc Braunstein: I agree, especially with the range of ages from 12 to 83. It's a pretty broad population by age, but I agree it does kind of reconcile those two groups in a disease that has a bimodal presentation and clearly shows that immune checkpoint inhibitors are both potent and well tolerated in different age groups.    Dr. John Sweetenham: The other question that I have about this study is we haven't seen so far in this study an overall survival benefit to the nivo arm, which is maybe not surprising, but in terms of the practice-changing potential of this study, do you think that will matter?   Dr. Marc Braunstein:  I think that's an excellent question, John. Initially, the ECHELON-1 study only showed progression-free survival, and then the update did show overall survival. And so if we take the lead from that study, we expect to see an overall survival benefit in the SWOG study as well with nivolumab, but it remains to be seen. But I think that the data presented thus far at the Plenary Session is compelling enough to consider using nivolumab upfront.   Dr. John Sweetenham: Yeah, I absolutely agree. And then I guess the other question that we're going to have to wait probably several years to know is what happens in terms of relapse? So, for the minority of these patients who do relapse, how salvageable, if that's the right word, are they going to be with a second- or third-line regimen? But I think that's clearly something for the future, and it's a very interesting, exciting outcome from this study.   Dr. Marc Braunstein: Absolutely.    Dr. John Sweetenham: Let's move on. Marc, again, we're still in the lymphoma world here, but looking at high-risk follicular lymphoma. And this was Abstract 7506, looking at epcoritamab plus the R2 regimen in patients with follicular lymphoma. Could you walk us through this one?    Dr. Marc Braunstein: Yeah, absolutely. Bispecific T-cell engaging antibodies are showing impressive efficacy in relapsed and refractory non-Hodgkin lymphoma. Epcoritamab is a bispecific antibody that binds to CD3 on T-cells and CD20 B-cells. And this antibody is currently approved for diffuse large B-cell lymphoma patients after two or more prior lines of treatment.    In this study presented by Merryman and colleagues, they explored the addition of epcoritamab to standard lenalidomide-rituximab. In 109 patients with relapsed or refractory follicular lymphoma who had at least one prior therapy, and, of note, the study was enriched for high-risk patients for progression, including those who had progression of disease within 24 months of their initial treatment and those patients who had been refractory to prior anti-CD20 treatment. This study enrolled 109 patients with relapsed refractory follicular lymphoma. The median age was 65 and 56% of patients had FLIPI scores on the higher end of the spectrum from three to five, and 61% had stage 4 disease. Also of note, 38% of patients had progression of disease within 24 months of their prior treatment. So at a median follow-up of 8.8 months, the overall response rate was impressive at 97%, and 82% of patients were still on treatment at that time.     Now, of course, with this mechanism of action of bispecific antibodies, there is a risk of both cytokine release syndrome and immune-related neurotoxicity. The rates of CRS were primarily low grade, there were only 2% grade 3, and of note, most occurred after the first dose. And in terms of ICANS or neurological toxicity, there were no grade 3 adverse events, and those occurred in only two patients. Finally, the estimated six months progression-free survival was 93%. So, if we cross-compare these results historically to the R-squared regimen, which was published to be about 80%, just cross comparing, so it's not exactly the same study, this clearly shows high activity on par or better with R-squared alone. Although this study was not a randomized study, I think the addition of epcoritamab certainly shows high overall response rates and we'll need randomized data to confirm the efficacy, but it's definitely encouraging in high-risk follicular lymphoma patients.   Dr. John Sweetenham: Thanks, Marc. I agree. I think these data are really enticing, in as much as the response rates are so high, but of course, it is follicular lymphoma, so we'll have to wait a while. But the thing that it does make me reflect on is that bispecific antibodies really are turning out to be remarkably effective in a range of B cell malignancies, so, it's very interesting to continue to watch this space.    I'm going to change gears now and talk about something completely different for a moment. And this was Abstract 1536. I think that many of us are in a position where we're now looking at how we deliver our clinical services, and particularly inpatient services, to patients with hematologic malignancy. And this study addressed that very specifically. Can I have your thoughts on that?   Dr. Marc Braunstein: Sure. In the context of how our therapies are improving, our approaches to how we manage patients clinically is changing too, in many ways for the better. So, various models exist for, you know, which practitioners manage oncology patients who happen to be admitted to the hospital. This abstract, which was performed by authors at a large medical center in New York, describes the use of a dedicated hematologic malignancy hospitalist for managing medicine-related issues. And the authors did comparisons of that service to a service primarily managed by oncologists. The authors compared things such as length of stay, whether the patients were discharged by noon, which is a hospital metric that's used for facilitating turnover of patients and space availability, as well as 30-day readmission rates among patients cared for by an oncology attending versus this heme malignancy hospitalist between July of 2021 and July 2022.    The outcomes showed that admissions to the heme malignancy hospitalists were, although less because that service was primarily for patients who required medicine-related issues as opposed to primarily oncologic issues, there were 95 admissions to that service versus 669 to the oncology service. There was a significantly shorter length of stay on the heme malignancies hospitalist service by about 2 to 5 days compared to the oncology hospitalist service. The rates of patients who were discharged by noon or the length of stay were similar between the two groups.    So, while this study is confounded by differences in acuity of disease between the services, using a dedicated heme malignancy hospitalist has many benefits, not just to offload the oncology-managed service, which may have a higher level of acuity, but also allow for a deviation of care for medicine-specific issues, to a hospitalist that's specifically trained in managing patients with hematologic malignancies and then dedicating the oncology specialty service to those who need acute oncologic care, such as those with leukemia or other high acuity diseases.    Dr. John Sweetenham: Thanks, Marc. I think it is really interesting to see some outcome data for this model of care. A number of centers I know are looking at an APP-led inpatient service for these types of patients, too, so it's going to be very interesting to see how further studies of these kinds of approaches continue to develop.    And on a related theme of changes in patterns of care, Abstract TPS1609 looked at home infusion and of course, this is something that really started to attract a lot more attention during the COVID-19 pandemic. But I wonder if you could walk us through some of the details of this poster.    Dr. Marc Braunstein: This study was presented as a poster proposing a prospective study looking at home infusion of the anti-CD38 monoclonal antibody daratumumab, which has a vital role in managing patients with newly diagnosed or relapsed multiple myeloma. And monoclonal antibodies have really revolutionized the care of patients with multiple myeloma, but often their infusion schedule is weekly or biweekly, and it does require relatively frequent visits to an infusion center.    So, this single-arm, open-label study is going to examine whether we can provide home administration of subcutaneous daratumumab and assess whether it improves quality of life and assess its safety. So, in this study, a visiting nurse will come and deliver the medication after patients take their pre-medications at home prior to the arrival of the infusion nurse. And then the investigators will provide quality of life questionnaires prior to and after the infusions and at the end of the study, and they'll be looking at any barriers to adherence, any barriers to the logistics of this home infusion arrangement.    And I think that this has a lot of potential not just to improve quality of life, but also to facilitate care to patients who may be frail, who may not have good caregiver support, who may have barriers in traveling to an infusion center or perhaps in places that are more resource-deprived and don't have local infusion centers. This could be a potential approach to delivering vital anti-myeloma medications at home, and I'm looking forward to seeing the results.    Dr. John Sweetenham: Yeah, I agree. I think a lot of us still have anxieties about the safety of this approach, but I think there are increasing data to suggest that home infusion is not only safe but also, as you mentioned, is a big enhancer of the quality of life of these patients. And so, very interesting to see how this plays out in prospective studies.    So, to close out, I wonder if you could walk us through Abstract 7072, a poster looking at the issue of clonal hematopoiesis.    Dr. Marc Braunstein: Clonal hematopoiesis, which is a phenomenon in which the blood cells acquire somatic mutation, is associated with both cardiovascular disease adverse outcomes as well as hematologic malignancy. It's been shown to be a precursor for diseases such as leukemia. So, this relatively small study from MD Anderson Cancer Center examined clonal hematopoiesis in 78 patients with malignancies, 70% of which had a history of cancer, and the authors described outcomes associated with clonal hematopoiesis.    So, again, 78 patients were examined, and 76% of them had a history of malignancy, and 73% had other comorbidities. And the authors demonstrated clonal hematopoiesis by the finding of specific mutations in the blood associated with clonal hematopoiesis. The authors essentially looked at outcomes such as mortality. They noted that only 20% of the patients developed a myeloid neoplasm, and that's relevant because, again, clonal hematopoiesis is a precursor for myeloid neoplasms. They also noted that most patients had died from a primary malignancy rather than a myeloid neoplasm, which is not too surprising considering that most patients with clonal hematopoiesis will not develop a hematologic malignancy, but it is a marker for the potential transformation.    And so, I think the authors conclude that clonal hematopoiesis is important for monitoring patients who are at risk for potential myeloid transformation and hematologic malignancy, but it's not necessarily the case that patients who have a background of malignancy will often develop a myeloid malignancy. I think there are many implications of clonal hematopoiesis for cancer in general in terms of the risk of secondary malignancies in those treated with adjuvant chemotherapy, in terms of how we monitor patients who actually more and more are going to have this detected as we use more next-generation sequencing and liquid biopsies.     So, I look forward to future studies that are exploring how to actually prospectively assess clonal hematopoiesis and use it for clinical stratification for things like adjuvant chemotherapy or monitoring for risks of hematologic malignancy.    Dr. John Sweetenham: Thanks, Marc. I agree. Very important for the future, especially as we gain more and more sequencing data.    So, Marc, in conclusion, I want to thank you very much for sharing your insights with us today on the ASCO Daily News Podcast. It's been great to talk with you again.    Dr. Marc Braunstein: My pleasure. Happy to be back, and I look forward to a future podcast session.  Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the abstracts discussed today in the transcripts of this episode. Finally, if you value the insights that you hear on ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    Find out more about today's speakers:   Dr. John Sweetenham   Dr. Marc Braunstein   @docbraunstein      Follow ASCO on social media:    @ASCO on Twitter    ASCO on Facebook    ASCO on LinkedIn       Disclosures:   Dr. John Sweetenham:   Consulting or Advisory Role: EMA Wellness   Dr. Marc Braunstein:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb/Celgene, Adaptive Biotechnologies, GlaxoSmithKline, ADC Therapeutics, Janssen Oncology, Abbvie, Guidepoint Global, Epizyme, Sanofi, CTI BioPharma Corp   Speakers' Bureau: Janssen Oncology   Research Funding (Institution): Janssen, Celgene/BMS        

Dr. John Sweetenham and Dr. Marc Braunstein discuss the role of maintenance therapy in high-risk multiple myeloma, advances in myelodysplastic syndromes in the COMMANDS study, the promise of bispecific antibodies in the pivotal EPCORE NHL-1 in relapsed/refractory large B-cell lymphoma, and improving outcomes for patients with chronic lymphocytic leukemia in the CAPTIVATE trial.  TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, the associate director for cancer network clinical affairs at UT Southwestern's Harold C. Simmons Comprehensive Cancer Center, and host of the ASCO Daily News Podcast. My guest today is Dr. Marc Braunstein, a hematologist and oncologist at the NYU Perlmutter Cancer Center. Today, we'll be discussing key posters and oral abstracts highlighting advances in hematologic malignancies that will be featured at the 2023 ASCO Annual Meeting.   You'll find our full disclosures in the transcript of this episode, and disclosures of all guests on the ASCO Daily News Podcast are available on our transcripts at asco.org/DNpod.  Dr. John Sweetenham: So, Marc, thanks for returning to us and coming to join us on the podcast today. Dr. Marc Braunstein: Thanks for inviting me back. Dr. John Sweetenham: I'd like to start out with Abstract 8001. This is a study which is addressing the role of maintenance therapy in patients with high-risk multiple myeloma. Could you take us through this study and the key take-home points that you think are the most important ones? Dr. Marc Braunstein: Sure, absolutely. So, the first abstract that we're going to discuss is an oral abstract being presented by Dr. Nooka regarding maintenance therapy in high-risk multiple myeloma patients. Outcomes of patients with multiple myeloma are clearly improving, yet those with high-risk cytogenetic abnormalities, which represent about 10-20% of all multiple myeloma, tend to have poorer survival, and worst among these are those with what's called ultra-high-risk or double-hit multiple myeloma who have more than 1 high-risk cytogenetic abnormality. So, this study looked at maintenance therapy following stem cell transplantation in 26 high-risk patients, about 59% of whom had double hit disease, representing very high-risk disease. This was a phase II study looking at using carfilzomib, pomalidomide, and dexamethasone in high-risk multiple myeloma patients who achieved at least a partial remission following stem cell transplant. There were 26 patients enrolled. The median age was 60. Of note, about 59% of patients were Black, which is important because these patients tend to be historically underrepresented in studies. And what they found was that at study entry, about 24% of patients were in a complete remission or better, and that deepened to 79% while on the study. And the median time to best response was 2 months, which is fairly brisk. With a median follow-up of about 26 months, the 36-month progression-free survival was 63%, and the overall survival was 72%, which is impressive, again in the context of patients who have very high-risk disease. So, although it remains to be determined what the optimal regimen or duration of maintenance should be in multiple myeloma, clearly, combination therapy is effective and should be used in patients who have high-risk or ultra-high-risk multiple myeloma. Dr. John Sweetenham: Great. Thanks, Marc. So, as you say, I mean, clearly the take-home message is around the effectiveness of this type of maintenance therapy. I just have a couple of quick follow-up questions for you. The first of those is, where do you see this going next? I mean, in your opinion, what would be the next logical study with this combination or similar combinations? And then secondly, what do you see on the horizon for those patients with very high-risk myeloma, particularly the double-hit population that you just mentioned? Dr. Marc Braunstein: It's a paradigm in multiple myeloma that combination therapy tends to be more effective as long as we're able to manage the adverse events that come with additional combinations. And we've been able to succeed in that regard with quadruplet regimens, even now that we have monoclonal antibodies that tend to be better tolerated and more targeted in nature. In terms of maintenance therapy, single-agent lenalidomide has been the long-standing agent of use for the majority of patients. But we now understand that the combination of an immunomodulator like lenalidomide and a proteasome inhibitor like bortezomib or carfilzomib is more effective for patients with higher risk disease.   We also have data from various upfront studies of quadruplet regimens, such as the FORTE study, which looked at carfilzomib and lenalidomide maintenance after transplant that shows that we can improve progression-free survival in all comers with multiple myeloma following transplants. So, I think down the road we're going to be looking at more use of combination therapies and maintenance. And as far as for high-risk patients, whether that's going to be using monoclonal antibodies in maintenance or combination proteasome inhibitors and immunomodulators or even other immunotherapies like bispecific antibodies as maintenance in the future remains to be determined, but clearly, for high-risk patients, we should be using combination therapies. Dr. John Sweetenham: Thanks, Marc. Let's change gears a little now and take a look at Abstract 7003, which addresses patients with myelodysplastic syndrome. This study addresses the efficacy and safety results from a study of luspatercept versus epoetin alfa in low-risk myelodysplastic syndrome. I wonder if you could describe this study and the results to us and maybe also for the benefit of our listeners, just mention quickly the mechanism of action of the experimental agent here.  Dr. Marc Braunstein: This is an oral abstract being presented by Dr. Garcia-Manero looking at a phase 3 study, as you mentioned, called the COMMANDS study, and this is looking at an agent called luspatercept in patients with low-risk myelodysplastic syndrome (MDS). So, patients with MDS can have inferior quality of life and survival when they become transfusion dependent. An earlier study called the MEDALIST study, which was published in the New England Journal of Medicine in 2020, randomized low-risk or intermediate-risk patients with MDS who were refractory or unlikely to respond to erythropoietin stimulating agents to either luspatercept, which is an agent that binds to TGF-beta family members and helps stimulate erythropoiesis. Patients were randomized in the MEDALIST study to luspatercept or placebo. And that study showed that luspatercept could improve a degree of anemia and lead to transfusion independence in certain patients. So, the COMMANDS study is a randomized controlled study that randomized 354 patients with low-risk MDS who were transfusion dependent and naive to an erythropoietin stimulating agent to receive either luspatercept or the erythropoietin stimulating agent erythropoietin alfa with the primary endpoint of transfusion independence at some time between 12 to 24 weeks. So, patients were randomized 1:1 to receive either luspatercept or epoetin alfa, and the primary endpoint again was transfusion independence. So, 354 patients were randomized in the study and the median treatment durations were 42 weeks of luspatercept and 27 weeks of epoetin alfa. And transfusion independence occurred in greater quantity in the patients who got luspatercept. For example, in the patients who received luspatercept at 8 weeks, transfusion independence was achieved in 74 versus 51% in the epoetin alfa group. So, in terms of treatment-related adverse events, they were fairly similar between the groups and consistent with the classes -  they were reported in 30% in the luspatercept group and 17% in the erythropoietin group, with no difference in patients who progressed to acute myeloid leukemia.  So, I think when it comes to MDS in low-risk patients, it's really important to preserve their quality of life by limiting their transfusion burden. And I think this study demonstrates that luspatercept continues to be an important part of the management in these low-risk patients. And whether or not you would start a patient with low-risk transfusion-dependent MDS on an erythropoietin stimulating agent or luspatercept is really addressed by this study showing that you can achieve greater rates of improvement in anemia and transfusion independence with luspatercept.  Dr. John Sweetenham: Great. Thanks, Marc. A really interesting study. And I do have one question for you about this study, which I think will make it clear to you that I am an expert neither in myelodysplastic syndrome nor in erythropoiesis. But my question is based on the mechanism of action. Is there any rationale for combining these 2 agents in future studies?  Dr. Marc Braunstein: Yes, it would potentially make sense to use 2 synergistic mechanisms to improve erythropoiesis. We would have to see what the potential for adverse events are. I think epoetin alfa tends to be a fairly low burden in terms of its side effect profile. Luspatercept can have some potentially dose-limiting side effects, such as GI side effects, but you can make dose adjustments to both of these medications. So we may need to find the correct doses of either of them in combination. But from a theoretical standpoint, it makes sense that these could potentially be synergistic, especially in patients who are likely to respond to erythropoietin by having a baseline lower erythropoietin level. Dr. John Sweetenham: Okay, let's move on in another change of gear now. And for the rest of the podcast, we're going to be talking about some studies in lymphoid malignancy, beginning with Abstract 7535, which is a follow-up of the phase 2 CAPTIVATE study which now has significantly extended follow-up from the original report. So Marc, can you walk us through this study and the outcomes to date? Dr. Marc Braunstein: Absolutely. So this is a poster being presented by Dr. Barr and it is looking at CLL, which is a field that is really moving away from chemotherapy for newly diagnosed patients, thanks to the development of novel targeted agents. The CLL14 trial, which was published in the New England Journal of Medicine in 2019, showed that fixed-duration venetoclax plus obinutuzumab improved progression-free survival and rates of negativity of minimal residual disease, or MRD, when compared to chlorambucil and obinutuzumab. So building on the success of that study, combining a monoclonal antibody and a BCL2 inhibitor, the CAPTIVATE study is a phase II study, which examines venetoclax with ibrutinib, the BTK inhibitor, and previously untreated CLL. So it's kind of combining 2of the novel targeted therapies in a fixed duration, similar to what was done in the CLL14 study where patients received 1 year of therapy and then stopped treatment.   So in the CAPTIVATE study, 154 patients were enrolled. This was a phase 2 study that included about 56% of higher-risk patients who had unmutated IGHV, and the median time on the study was 50 months, with a CR rate of 58% at a 4-year follow-up and an overall response rate of 96%, which is quite high, especially considering that more than half of patients had high-risk disease. The progression-free survival was 79% and the overall survival rate was 98% at 4 years. And when they looked at patients who had undetectable minimal residual disease, the 4-year overall survival rate was 100%, which also suggests that MRD can help serve as a predictive marker of longer-term survival. So I think we have to also consider what the side effects are of combining these 2 agents and the most common adverse events were hematologic, which is expected based on what we know about the 2 classes. So I think the implication of the study is that giving 2 oral agents for a fixed period of treatment for 12 cycles is a rational approach that may spare patients indefinite therapy and can lead to positive outcomes, including in patients who have high-risk features with CLL.  Dr. John Sweetenham: Yeah, the other interesting observation that was made in the abstract, which I found to be really encouraging, was the fact that a number of these patients apparently have been re-treated successfully upon progression with ibrutinib again, which seems to be somewhat reassuring as well.  Dr. Marc Braunstein: That's right. There were 4 patients who started re-treatment in the study and perhaps we'll see the outcomes of that small subgroup are at the poster presentation. But I think when we discuss fixed-duration treatment, it also opens the door to potentially re-challenging patients when they relapse. We know that when we stop single-agent BTK inhibitors, which are historically given indefinitely in patients with CLL, those patients who stop, many will relapse, but you can potentially re-challenge them with the BTK inhibitor. So this study with the CAPTIVATE trial gives us some liberty to discontinue therapy, but also considering re-challenging upon relapse.   Dr. John Sweetenham: Yeah, absolutely. Moving on to aggressive B-cell lymphoma, now, the next abstract I'd like to discuss with you is Abstract 7525. I find this one particularly interesting as the continued excitement around CAR T cell therapy for relapsed aggressive lymphoma remains high at the moment. It's intriguing that t cell-engaging antibodies also have been reported, at least, to have remarkable activity in this set of diseases. So can you take us through Abstract 7525 and what they're reporting?  Dr. Marc Braunstein: Absolutely. Bispecific antibodies represent an emerging field in multiple hematologic malignancies, and this is a class of antibodies that bind to both the tumor cell as well as T-cells, and activate T-cell immunity against the tumor cell. So epcoritamab is a bispecific antibody that binds to CD3, which is expressed on T cells, and CD20, which is expressed on B cells. And Thieblemont et al published results in the Journal of Clinical Oncology last year in a phase I/2 study that looked at epcoritamab in patients with diffuse large B cell lymphoma following 2 prior lines of therapy, and this was given subcutaneously until progression of disease. In that study, at a median follow-up of about 11 months, the overall response rate was 63% with 39% complete remissions.   So the EPCORE NHL-1 study, which is being presented at this year's ASCO meeting, is presenting the updated results of that study looking at patients with diffuse large B cell lymphoma that includes a small population as well of patients with high-grade B cell lymphomas and primary mediastinal B cell lymphomas who had at least 2 prior lines of therapy. In this presentation, 157 patients were included in this study, and 61% had primary refractory disease, and actually, 39% had prior CAR T-cell therapy, of whom 75% progressed within 6 months. So these were patients who were not only refractory to treatment but also had prior T-cell therapy.   So at a median follow-up of 20 months, the overall response rate was 63% and the complete response rate was again about 39%, and the median duration of complete remission was 21 months. In terms of overall survival, the median was about 19 months, which is substantial for this group of patients who really wouldn't be expected to respond very well to conventional therapies.   As we know, T-cell-engaging therapies, such as these bispecific antibodies or CAR T-cells have the potential risk for certain immune-related adverse events, including cytokine release syndrome or icons, and a neurologic syndrome related to the therapy. And it's worth noting that the CRS in this study was predominantly low-grade. There were only 3% of patients who had grade III CRS, and 9 patients, or 6% had grade I to II icons. I think that also reflects how we're better managing those side effects and intervening earlier. So I think the results are impressive from the standpoint of the population studied, who were quite refractory to treatment and show relatively high rates of response. In fact, the median overall survival was not reached in the overall population.   So I think what we take away from this abstract is that bispecific antibodies are going to play a vital role in the relapse-refractory setting for large cell lymphoma and may also offer an alternative to patients who aren't necessarily fit for CAR T-cell therapy, which plays a vital role in patients who are both refractory to first-line therapy or relapse-refractory to subsequent disease. So these are very encouraging results, and I'm sure we'll see randomized data as well in the future, further supporting the use of bispecific antibodies like epcoritamab.  Dr. John Sweetenham: Yeah, I agree. Thanks, Marc. I think that's a great summary. And it's particularly exciting to me that the investigators were able to achieve this kind of level of response and progression-free survival with a subcutaneous treatment. It's really quite remarkable and really exciting to see that.  We're going to wind up with our final abstract today, which is looking at the utilization of circulating tumor DNA in, again, in patients with aggressive B cell lymphoma. This is Abstract 7523, so maybe you could walk us through this one, Marc.  Dr. Marc Braunstein: Absolutely. So this is a poster being presented by Dr. Herrera looking at a, I guess you could call it a biomarker in the blood using circulating tumor DNA in patients with newly diagnosed diffuse large B cell lymphoma in the POLARIX study. So the results of the phase 3 POLARIX study were published last year in the New England Journal of Medicine and showed improvement in progression-free survival with the addition of these anti-CD79b antibody polatuzumab to standard R-CHOP chemotherapy compared to R-CHOP alone. And this study actually led to the approval of first-line treatment that includes polatuzumab.   In the abstract being presented by Dr. Herrera, the investigators looked at the value of circulating tumor DNA as a potential marker to serve as a guide for prognosis and predicting longer-term responses, particularly when the blood is cleared of circulating tumor DNA. So the study involved 654 patients who had ctDNA results both at baseline and then with longitudinal assessment, and they used an assay called the CAPP-Seq assay to assess circulating tumor DNA and assess for its clearance. In the study, undetectable circulating tumor DNA was achieved in 57% of patients who got the polatuzumab R-CHP combination and 59% of the patients who got R-CHOP by cycle 5 and then 6% in the polatuzumab group at 67% in the R-CHOP group.  So the rates of circulating tumor DNA clearance were similar between the 2 arms. But what's notable is that patients in the polatuzumab arm who achieved a complete response at the end of treatment plus cleared their circulating tumor DNA had superior progression-free and overall survival compared to patients who achieved a CR but retained circulating tumor DNA in their blood.   And this has implications because it might help gauge, for example, if patients may need additional cycles to clear the circulating tumor DNA, although we still need more data to answer whether that's necessary or not. And it may help serve as a predictive marker for longer-term remission, particularly in patients who perhaps have higher risk factors at baseline. So I don't think this is necessarily ready for primetime to use in clinical practice, but it is intriguing to know that we could finally have a tumor-specific biomarker in the blood to help monitor patients and potentially predict their longer-term remissions.  Dr. John Sweetenham: Thanks, Marc. I agree. Great summary, and obviously there's still something to learn about the kinetics of the response and so on. And also, I suppose it raises the question of whether those patients who still have detectable levels should be switched at the end of therapy to some kind of preemptive second-line therapy. And these are obviously all questions for the future, but it's going to be very interesting to watch this space, I think, and see how this story develops. Dr. Marc Braunstein: Absolutely. And my colleagues in the solid tumor space are already using circulating tumor DNA, for example, in colon cancer, to help with surveillance. So perhaps this could be a tool to use to predict relapse also in patients who are on surveillance after their treatment. But again, as you alluded to, we need more data to address that.  Dr. John Sweetenham: Well, thanks so much, Marc, for sharing your insights with us today on a really interesting set of abstracts coming up at the June meeting. And thanks for joining us on the ASCO Daily News Podcast. Dr. Marc Braunstein: Thank you for inviting me.  Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the abstracts discussed today in a transcript of this episode. Join us again after the annual meeting for key takeaways on the late-breaking abstracts and other key advances from the ASCO Annual Meeting. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:  Dr. John Sweetenham Dr. Marc Braunstein @docbraunstein   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Facebook  ASCO on LinkedIn  Disclosures: Dr. John Sweetenham:Consulting or Advisory Role: EMA Wellness Dr. Marc Braunstein:Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb/Celgene, Adaptive Biotechnologies, GlaxoSmithKline, ADC Therapeutics, Janssen Oncology, Abbvie, Guidepoint Global, Epizyme, Sanofi, CTI BioPharma Corp Speakers' Bureau: Janssen OncologyResearch Funding (Institution): Janssen, Celgene/BMS

Synopsis: Harlan Robins, Ph.D., is the CSO and Co-Founder of Adaptive Biotechnologies, a pioneer and leader in immune-driven medicine that aims to improve people's lives by learning from the wisdom of their adaptive immune systems. Adaptive's proprietary immune profiling platform reveals and translates insights from our adaptive immune systems with unprecedented scale and precision. Harlan discusses how he navigated the ups and downs of co-founding a company. He talks about the adaptive immune system, why it's important, and what Adaptive is currently working on from a development perspective. He also discusses Adaptive's partnership with Genentech to create personalized cancer therapies. Biography: Dr. Harlan Robins is the Chief Scientific Officer and Co-Founder of Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Prior to co-founding Adaptive, Harlan served in various roles at the Fred Hutchinson Cancer Research Center (FHCRC) in the Computational Biology Program, including Assistant Faculty Member, Associate, and Full Member and Head of the program. Harlan holds a BS in Physics from Harvard University and a master's degree and PhD in Physics from the University of California, Berkeley, with a visiting appointment to the California Institute of Technology. Harlan received postdoctoral appointments in the particle theory group at the Weizmann Institute of Science in Israel. Interested in the mathematics behind genetics and observing the potential utility of high-level mathematics to study problems in the biological sciences, Harlan took another postdoctoral appointment at the Institute for Advance Study in Princeton under famed biologist Dr. Arnold Levine. With Dr. Levine, he concentrated on developing bioinformatic algorithms for micro RNA targets and bacterial genome analysis, a precursor to his faculty appointment at FHCRC in the Computational Biology Group, Public Health Sciences and Human Biology Divisions.

Great green stocks and healthy health stocks found in these articles: “Ten Green Stocks I expect to do well over the next year”; “Top Health Care Stocks To Buy Right Now? 4 To Watch”; “Top 5 Companies That Pledged To Go Carbon Neutrality”; and “Best Stocks To Buy Now? 4 Renewable Stocks For Your List.” Podcast: Great Green Stocks Transcript & Links, Episode 87, July 15, 2022 Hello, Ron Robins here. Welcome to my podcast episode 87 published on July 15, 2022, titled “Great Green Stocks” — and presented by Investing for the Soul. Investingforthesoul.com is your site for vital global ethical and sustainable investing mentoring, news, commentary, information, and resources. Remember that you can find a full transcript, and links to content – including stock symbols, quotes, and bonus material – at this episode's podcast page located at investingforthesoul.com/podcasts. Now if any terms are unfamiliar to you, simply Google them. Also, just a reminder. I do not evaluate any of the stocks or funds mentioned in these podcasts, nor do I receive any compensation from anyone covered in these podcasts. Furthermore, I will reveal to you any personal investments I have in the investments mentioned herein. ------------------------------------------------------------- 1. Great Green Stocks This first article is titled Ten Green Stocks I expect to do well over the next year by Tom Konrad. It appeared on altenergystocks.com. I've covered Mr. Konrad's picks before, so this is an update. His picks are followed by brief comments on each one. “1) MiX Telematics (NASD: MIXT) A provider of vehicle tracking and telematics to large international vehicle fleets.  The company is green because it both reduces accidents and fuel usage for its customers. 2) Valeo, SA (FR.PA or US ADR: VLEEY or US foreign stock ticker: VLEEF) A provider of electrified drive trains, sensors, and comfort systems for the automotive industry. 3) NFI Industries (NFI.TO C$13.39 or US foreign stock ticker: NFYEF) A leading international bus and motorcoach manufacturer selling a large and growing number of electrified vehicles. 4) Rockwool A/S (ROCK-B.CO and ROCK-A.CO or US foreign stock ticker: RKWBF) A manufacturer of fire and mold resistant building insulation. 5) Hannon Armstrong Sustainable Infrastructure (NASD: HASI) A financier of solar, wind, biogas, and energy efficiency installations. 6) Veolia (VIE.PA or US ADR: VEOEY or US foreign stock ticker: VEOEF) A large international developer and operator of municipal infrastructure such as water, wastewater, recycling, and environmental remediation. 7) Enviva, Inc (EVA) A vertically integrated wood pellet supplier to European and Japanese markets, where they mostly displace coal in electricity generation. 8) Umicore, SA (UMI.BR or US ADR: UMICY or US foreign stock ticker: UMICF) A vertically integrated recycler of hard-to-recycle and specialty metals used in clean energy industries such as batteries, solar, wind, and catalytic converters. 9) Avangrid (NYSE: AGR) One of the top producers and developers of renewable electricity in the United States.   10) Atlantica Sustainable Infrastructure (NASD: AY) An international owner and developer of renewable energy, efficient natural gas, electric transmission line and water assets.” End quotes. ------------------------------------------------------------- 2. Great Green Stocks This next article recommends some leading health care stocks. Many ESG portfolios contain the healthcare stocks in this article titled Top Health Care Stocks To Buy Right Now? 4 To Watch by Joe Samuel at StockMarket.com. Here are some quotes by Mr. Samuel on each one. Quote. “1) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) This is a company that focuses on the development of medicines… for the underlying cause of cystic fibrosis (CF)… Vertex also has a pipeline of investigational therapies in other serious diseases… This includes sickle cell disease, type 1 diabetes, pain, beta-thalassemia, and more… The company announced earlier this week that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on its Phase 1/2 clinical trial of VX-880. The drug is an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes.  Furthermore, Vertex also signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA)… Not only is this a huge milestone for the company, but this new recommendation will be a huge boost for all people living with CF in Canada. So, would you consider Vertex Pharmaceuticals stock as a top health care stock to buy? 2) Novavax (NASDAQ: NVAX) This is a biotech company that specializes in developing vaccines to treat infectious diseases… the company's portfolio consists of vaccines for Ebola, influenza, and respiratory syncytial virus among other emerging infectious illnesses… the company is actively working on a coronavirus vaccine. Novavax stock is among the most bullish stocks in the health care sector today… The latest (development) that contributed to its momentum (is) its Nuvaxovid COVID-19 vaccine… the European Commission gave the green light for conditional marketing authorization of the vaccine in the European Union for adolescents aged 12 through 17… Keeping this in mind, would you consider jumping on the Novavax stock bandwagon?  3) Adaptive Biotechnologies (NASDAQ: ADPT) Similar to Novavax, Adaptive Biotechnologies is a company that has been quietly building momentum recently. For those unaware, it is a commercial-stage company that focuses on the human adaptive immune system to develop the diagnosis and treatment of diseases… For now, the company's commercial research products include immunoSEQ and immunoSEQ T-MAP… In June, the company launched the T-Detect™ Lyme. This is a test… that will identify… Lyme disease… With that in mind, should investors keep a closer tab on Adaptive Biotechnologies stock?  4) Beam Therapeutics (NASDAQ: BEAM) Is a biotech company that focuses on precision genetic medicines based on its base editing technology… Therefore, it would not be surprising if investors will be paying more attention to BEAM stock moving forward… Recently, it appears that the company has entered into an amended and restated collaboration and license agreement with Verve Therapeutics (NASDAQ: VERV). Under the amendment, Beam granted Verve a license toward an additional liver-mediated cardiovascular disease target… Overall, these new amendments appear to be a positive development. Having said that, does BEAM stock have a spot on your watchlist?” End quotes. ------------------------------------------------------------- 3. Great Green Stocks Now, do you want to invest in the Top 5 Companies That Pledged To Go Carbon Neutrality -- and yes, that's the title of this next article! It's by Samiya Saeed. It's found on inventiva.co.in. Here are a few quotes from Ms. Saeed on each company. “1) GOOGLE (GOOG) In 2017, Google became the first company to meet 100% of its yearly worldwide electricity needs with renewable energy… it has promised to decarbonize its electricity supply and run-on carbon-free energy seven days a week, 24 hours a day, by 2030. 2) Apple (AAPL) By 2030, Apple's entire business, manufacturing supply chain, and product life cycle would all be carbon neutral, the company announced in July 2020. According to the company, nearly 70 suppliers have committed to using only renewable energy in their manufacturing processes… The company also said in March that the 2022 iPhone SE would be the first device to use its carbon-free aluminum smelting technology. The 16-inch MacBook Pro is likewise manufactured with low-carbon aluminum. Apple is also spending money on afforestation and other environmentally friendly methods to sequester carbon. 3) INTEL (INTC) Intel, has made a commitment to becoming carbon neutral by 2040 as well as to increase energy efficiency and lessen the carbon impact of its platforms and products… The corporation aims to use solely renewable energy in all of its international operations by that time. Intel will invest $300 million in energy-saving measures at its facilities, saving a total of 4 billion kilowatt-hours. Additionally, the company will build new buildings that meet the requirements of the US Green Building Council's LEED program in Europe, Asia, and the United States. 4) MICROSOFT (MSFT) Microsoft has committed to becoming carbon neutral by 2030. The company also claims that by 2025, it will have either directly or indirectly eliminated from the environment all of the carbon it has released into the atmosphere since its foundation in 1975. To hasten the global development of carbon reduction, capture, and removal technologies, it has established a $1 billion climate innovation fund. 5) IBM (IBM) IBM stated in February that it would have zero net greenhouse gas emissions by 2030.” End quotes. ------------------------------------------------------------- 4. Great Green Stocks Now we return to renewable energy stocks with this article titled Best Stocks To Buy Now? 4 Renewable Stocks For Your List by Jonathan Phillip from StockMarket.com. Here's some of what Mr. Phillip says about his picks. “1) Clearway Energy (NYSE: CWEN) The company is one of the country's largest renewable energy owners. Impressively, the company has over 5,000 net megawatts (MW) of installed wind and solar generation projects… Its 7,500 net MW of assets also include approximately 2,500 net MW of environmentally sound, highly efficient natural gas generation facilities… Last week, the company announced that it has entered into an agreement with Capistrano Wind Partners to acquire its operating wind projects… these wind projects would be a perfect fit for Clearway's current portfolio… The acquisition… should boost Clearway's financials from 2023. Given this acquisition, should you invest in Clearway stock? 2) JinkoSolar (NYSE: JKS) One out of every ten solar modules in the world is produced by JinkoSolar. Since the start of the year, JinkoSolar stock has risen nearly 40% in price. Earlier this month, JinkoSolar kicked off the construction of its latest n-type solar cell and module production plant in Jianshan in China. On this site, the company will produce 11 gigawatts (GW) of n-type cells with an average efficiency of 25%. This would mean that JinkoSolar could be the world's first 10 GW-scale factory to mass-produce solar cells of above 25% efficiency… With JinkoSolar making these advancements, should you keep an eye out for JKS stock? 3) First Solar (NASDAQ: FSLR) The company engages in the manufacture of solar panels and utility-scale photovoltaic (PV) power plants. Besides that, it is a global provider of sustainably produced eco-efficient solar modules. The company's advanced thin-film photovoltaic (PV) modules represent the next generation of solar technologies… Last week, the company inked an agreement to supply 2 GW of its solar modules to National Grid Renewables (NGR), further strengthening its partnership with the company… Through this, it would seem that First Solar's long-standing relationship with National Grid Renewables exemplifies the capabilities of its products. Therefore, should you add First Solar stock to your portfolio? 4) NextEra Energy (NYSE: NEE) It is a renewable energy company that owns the largest rate-regulated electric utility in the U.S., Florida Power & Light Company (FPL)… (which) serves more than 11 million residents across Florida with clean, reliable, and affordable electricity. It also owns a competitive clean energy business, NextEra Energy Resources (NEER)… one of the largest generators of renewable energy from the wind and sun and a world leader in battery storage… The renewable energy giant announced that it will be purchasing the wastewater system of Towamencin Township in Montgomery County, Philadelphia… NextEra's management recently increased its earnings per share expectations for the 2022 to 2025 period… Considering the news, is NextEra Energy stock worth watching?” End quotes. Incidentally, JinkoSolar is still accused by some of employing forced labor. ------------------------------------------------------------- Other Honorable Mentions – not in any order, links on this podcast's webpage 1) Title ETFs for investors willing to ride out the volatility in the clean energy sector - theglobeandmail.com. By Joel Schlesinger. 2) Title DividendChannel: Top Socially Responsible Dividend Stock - VerizonPR (5.0% Yield) on coinsobserver.com. 3) Title Schlumberger a Top Socially Responsible Dividend Stock With 2.1% Yield (SLB) on nasdaq.com. By BNK Invest. 4) Title 5 Best Robo-Advisors for Socially Responsible Investing – CEO Money on wfn1.com. By Barbara Friedberg. 5) Title This Solar Stock Continues To Rise As Consumers Seek Alternative Energy in Investor's Business Daily at investors.com. By Michael Molinsky. Plus an article for UK investors — again link on this podcast's webpage Title Want to invest ethically and cheaply? Find a responsible tracker fund on thisismoney.co.uk. By Tanya Jeffries. ------------------------------------------------------------- Ending Comment Well, these are my top news stories with their stock and fund tips -- for this podcast: “Great Green Stocks.” To get all the links, and stock symbols, or to read the transcript of this podcast -- and more -- go to investingforthesoul.com/podcasts and scroll down to this episode. Also, be sure to click the like and subscribe buttons in Apple Podcasts, Google Podcasts, or wherever you download or listen to this podcast. And please click the share buttons to share this podcast with your friends and family. Let's promote ethical and sustainable investing as a force for hope in these deeply troubled times! Contact me if you have any questions. Thank you for listening. Talk to you next on July 29. Bye for now. © 2022 Ron Robins, Investing for the Soul

Dr. Sonali Smith, of University of Chicago Medicine, highlights dynamic sessions and hot topics that will be featured in the 2022 ASCO Annual Meeting Scientific Program, including practice-changing advances in breast cancer, colorectal cancer, sarcoma, and myeloma.     Transcript  ASCO Daily News: Hello and welcome to the ASCO Daily News podcast. I'm Geraldine Carroll, a reporter for the ASCO Daily News. I'm delighted to welcome Dr. Sonali Smith, professor and chief of the hematology-oncology section at University of Chicago Medicine.  Dr. Smith is also the Chair of the 2022 ASCO Annual Meeting Scientific Program and joins me to discuss the hot topics and must-see sessions that will be featured at the meeting.  Her full disclosures are available in the show notes and disclosures relating to all guests on the podcast can be found on our transcripts at asco.org/podcasts.  Dr. Smith, it's great to have you on the podcast today.  Dr. Sonali Smith: Thank you, Geraldine. It's a pleasure to be here.  ASCO Daily News: Well, thousands of abstracts were submitted for consideration this year and more than 2,900 were selected for presentation. We'll talk about some of the must-see sessions. First, can you tell us about the areas that have shown tremendous advances this year—the practice-changing abstracts that will make the headlines?  Dr. Sonali Smith: Yes, that's right. There were over 6,000 abstracts submitted for consideration this year and more than 2,900 abstracts were selected for presentation with over 250 oral presentations. We had 2,200 that were online publication only. And given the hybrid nature of ASCO [Annual Meeting] this year, we will have 86 sessions that will be livestreamed, including all of our abstracts that are oral.  I'm really excited about the Plenary. In particular, there are going to be some practice-changing abstracts involving breast cancer, colon cancer, sarcoma, and myeloma. We are really thrilled with the quality and the excitement around the data and I do think this is going to be very important for people who are in practice.  When we think about the different abstracts that have been submitted for the Plenary, they will focus on front-line colon cancer, the approach to Ewing sarcoma in pediatric patients, and the use of antibody-drug conjugates for breast cancer in a very specific subset. And then also some discussion about, or presentation about, the use of maintenance therapy in patients with myeloma.  ASCO Daily News: Excellent. Well, the Clinical Science Symposia are quite popular among participants. Can you tell us about some of the topics that will be featured this year?  Dr. Sonali Smith: Yes. So, the Clinical Science Symposia (CSS) were really a lot of fun to pull together. As this audience knows well, this is an opportunity for us to take a look at all of the abstracts submitted and look for cross-cutting themes between all of the different cancers that we take care of. They can focus on new technology. They can focus on new approaches to therapy. And after looking at all of the submitted data, we have 3 really outstanding special Clinical Science Symposia for which I'm really excited.  One is going to focus on circulating tumor DNA, “ctDNA: Dawn of a New Era,” and I really do believe in that title and encourage everybody to come and hear how this could be applied in practice.  The second special CSS will be on Bispecifics. Really asking the investigators as well as the discussants. “Bispecifics: Are Two Better Than One?” And then the third special Clinical Science Symposium will be called, “Is There a Ghost in the Machine? Putting Artificial Intelligence to Work.” And as many of us know, machine learning is finally finding its way into oncology. And I'm just thrilled at the abstracts that have been submitted.  I also just wanted to say that we've had a really outstanding speaker lineup and it's incredibly diverse with international perspectives brought to the table.  ASCO Daily News: Absolutely. And so, what are some of the other sessions that will be on your own list this year?  Dr. Sonali Smith: Well, I'm really excited about the opening session, which will be at 9:30 in the morning on Saturday, June 4th. We will have our president, Dr. Everett Vokes, speaking on his theme, Advancing Equitable Cancer Care Through Innovation.  We also have our FASCO presentations, and we have 2 special speakers. One will be Ned Sharpless, who is the head of the National Cancer Institute. And then we will also have Dr. Andre Ilbawi, who is the lead of cancer programs at the World Health Organization. He has had an incredible impact on improving access for children with cancer on a global level. And I think this series of speakers really fits with our theme this year.  Another session I'm really looking forward to is the [David A.] Karnofsky [Award and] lecture by this year's widely respected speaker, Dr. Jedd Wolchock. This is anticipated to be an incredibly thought-provoking and clinically relevant presentation, and I hope all of you will join us.  ASCO Daily News: In following up then on the theme of the meeting this year, it is, of course, Advancing Equitable Cancer Care Through Innovation, can you comment on how important it is that this theme is represented in as many of these programs, as many of these sessions as possible at meetings such as the [2022] ASCO Annual Meeting and other symposia?  Dr. Sonali Smith: A global approach and a global mentality when we are developing therapies, preventive approaches, are really incredibly important. In the United States, at least, the survival for patients with cancer has doubled, and I think it is really important to remember that we are a global organization and there are many people around the world who can benefit. And if we can put innovation into this, hopefully, it can be done better and faster.  ASCO Daily News: Absolutely! Well, thank you so much, Dr. Smith, for taking the time to be on the podcast today and for sharing some of these highlights. And a big thank you for your efforts to create a really robust scientific program for the 2022 ASCO Annual Meeting.  Dr. Sonali Smith: Thank you so much. It's been a real pleasure.  ASCO Daily News: And thank you to our listeners for your time today. If you're enjoying the content on the ASCO Daily News podcast, please take a moment to rate, review and subscribe wherever you get your podcasts.      Disclosures:   Dr. Sonali Smith has been paid for any consulting or advisory role by ADC Therapeutics , Adaptive Biotechnologies , Gilead Sciences, Bristol Myers Squibb, MorphoSys, Janssen, Bantam Pharmaceutical, and Karyopharm Therapeutics, currently or during the past 2 years. Dr. Smith has received research funding from Portola Pharmaceuticals, Genentech, Acerta Pharma, Pharmacyclics, Celgene, Curis, Bristol Myers Squibb, TGTX, Merck, Forty Seven, and Novartis, currently or within the past 2 years.   Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   

While not yet mainstream in the community setting, measurable residual disease (MRD) testing has the potential to become more fully integrated into clinical practice as one of the reliable markers of treatment response for patients with multiple myeloma and chronic lymphocytic leukemia.Our guests—Drs. Rafael Fonseca and Tara Graff—discuss the benefits of MRD testing for these specific patient populations, the importance of training the multidisciplinary care team, and the promise of MRD testing to improve patient outcomes as its adoption continues to grow. Guests: Rafael Fonseca, MD Professor of Medicine, Mayo Clinic Scottsdale, Arizona Tara Graff, DO Medical Oncologist, Mission Cancer and BloodDes Moines, Iowa  This podcast is produced as part of the ACCC MRD Testing Implementation Roadmaps education project and is funded by Adaptive Biotechnologies.Resources: MRD Testing Implementation RoadmapsMRD Testing Implementation Roadmap for B-cell Acute Lymphoblastic LeukemiaMRD Testing Resource LibraryMultidisciplinary Multiple Myeloma CareBiomarkers in Hematologic Malignancies: A Focus on CLL and Multiple MyelomaMultidisciplinary Chronic Lymphocytic Leukemia Care

This is the first in a new CM Life Science series discussing trends and insights into the diagnostics market with industry leaders from across the globe. In this episode, I talk with Delphine Galezowski, Director of Market Development in Europe for Adaptive Biotechnologies. We discuss European market expansion strategies within the diagnostics space, the differences between European market access and other global territories, and insights from her time leading teams at AstraZeneca. Whether you're in the diagnostics industry, are intrigued by market access strategies, or are wondering how different organisations and regions differ within the market – then be sure to have a listen. In the following episodes my colleagues will be discussing a range of key trends and insights into key topics within the wider diagnostics market, too. So please subscribe to the series to be notified when their episodes become available. If you'd like to get in touch about this episode, would like to be a future podcast guest or want to learn more about CM Life Science's services; then please email me at eleanor.doolin@lifesci-cm.com.

Harlan Robins is the Chief Scientific Officer at Adaptive Biotechnologies in Seattle. In 2014, Harlan and his brother Chad co-founded Adaptive as a spinout from the Fred Hutchinson Cancer Center where Harlan had served as the head of computational biology. Adaptive has been developing what they call "immune medicine" mainly in the area of cancer. When the corona virus pandemic hit, they came out with the world's first T cell-based COVID diagnostic. The test has garnered them a lot of data on T cell response to COVID.

Gemma Milne talks with Chad Robins, co-founder and CEO of Adaptive Biotechnologies, about his company's work in the emerging field of immune medicine, how they use technology to drive innovation, and the potential for their work to create further advancements in the area of personalized medicine.Topics of discussionAn overview of immune medicine (4:10)An overview of Adaptive Biotechnologies' T Detect antigen map (5:11)The role of data and technologies such as machine learning in immune medicine (7:41)Developing the T Detect COVID test (10:11)How technology has shaped thinking around diagnostics and therapeutics (13:08)Key diagnostic challenges (17:13)Key treatment challenges (19:53)The role of AI in furthering personalized medicine innovations (22:23) About Chad Robins:Since its founding in 2009, Chad has led Adaptive Biotechnologies in building a proprietary immune medicine platform that fuels businesses across life sciences research, clinical diagnostics, and drug discovery. Chad is routinely recognized for excellence and innovation. In 2019 and 2020, he was included in the Puget Sound Business Journal's Power 100 and has been named a Goldman Sachs Most Intriguing Entrepreneur each year since 2015. He also named 2016 Ernst & Young Entrepreneur of the Year® – The Pacific Northwest Region Award.Learn more:https://www.adaptivebiotech.com Sponsor linkDynamics 365 delivers next generation ERP and CRM business applications, helping employees at every level reason over data, predict trends, and make proactive, more-informed decisions. Request a live demo of Dynamics 365 today:https://aka.ms/AA8vns5 Contact usEmail: connectedandready@microsoft.com Follow us on social mediaTwitter: https://twitter.com/msftdynamics365LinkedIn: https://www.linkedin.com/showcase/microsoft-dynamicsYouTube: https://www.youtube.com/channel/UCJGCg4rB3QSs8y_1FquelBQ

Adaptive Biotechnologies Corporation, Q3 2021 Earnings Call, Nov 03, 2021

Brian Finrow brings the skills and experience of a lawyer to a position that, in the biotech world, is more typically occupied by a scientist. This is essential to an enterprise like Lumen, which is rethinking drug development from the ground up to emphasize speed, efficiency and ease of delivery, and whose approach is so innovative that traditional ways of thinking about IP and regulatory pathways oftentimes do not apply. Prior to co-founding Lumen, Brian oversaw complex negotiations with various major biopharma companies and managed IP strategy for Adaptive Biotechnologies, where he was Senior Vice President and General Counsel. As Senior Attorney at the law firm Cooley LLC, his practice focused on equity financing and M&A transactions, and negotiating complex biotech licensing and collaboration deals. With over 15 years of legal and commercial experience at these market-leading, innovative firms, he is well positioned to develop creative, win-win deal structures with other organizations. Harvard Law School, JD Harding University, BS, Public Administration Harding University, BA, Political Science

In this episode, Lance Baldo, MD, discusses the use of MRD testing, T-cell receptor profiling, and how lessons from the COVID-19 pandemic will help shape the future of cancer vaccines. Welcome to another exciting episode of Oncology Overdrive :13 About Baldo :17 The interview 1:20 Tell me about your journey 1:38 Did you question your decision to leave clinical practice for an entrepreneurial venture? 2:36 What does Adaptive Biotechnologies do? 3:43 What is Minimal Residual Disease (MRD) testing and how is it used? 4:27 Are you looking only at hematologic malignancies? 5:35 How are experts using MRD testing in clinical practice? 6:31 Why do you think MRD testing is important in treating cancers? 7:24 Is Adaptive working on drug discovery and development related to MRD testing? 9:20 Personalized care and how real life feels like science fiction 12:02 Doing what's best for the patient 15:33 Tell me about T-cell receptor profiling 18:02 Tell me about neo-antigen-based therapy 21:10 Are these types of technologies available outside of large, academic institutions? 22:49 Has COVID impacted the way you and your team think about implementing therapies and innovation? 25:03 Do you think what we've learned over the last year will help with the creation of future cancer vaccines? 29:59 If we spoke again in 10 years, what would you hope to have done? 31:25 Baldo's take-home message 37:42 Where to find Baldo 38:57 Lance Baldo, MD, is chief medical officer of Adaptive Biotechnologies. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow us on Twitter @HemOncToday and @ShikhaJainMD. Baldo can be reached on LinkedIn, via email at lbaldo@adaptivebiotech.com and at www.adaptivebiotech.com.    Disclosures: Baldo is chief medical officer of Adaptive Biotechnologies. Jain reports she is a paid freelance writer for Lippincott.

Mark Adams is the Chief Operating Officer of Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Prior to joining Adaptive, Mark served as Managing Director, Healthcare Advanced Analytics, at SVB Leerink, a health and life sciences-focused investment bank, since April 2018. Mark has also served as Chief Information Officer at Celmatix, a women's health precision medicine company, from September 2016 to April 2018, and at Good Start Genetics, a molecular diagnostics company. Mark holds a BA from Oberlin College and a PhD from Baylor College of Medicine. See omnystudio.com/listener for privacy information.

Adaptive Biotechnologies Corporation, Q2 2021 Earnings Call, Aug 04, 2021

In this episode, Julie Rubinstein, MBA, discusses her journey into the cancer space, the importance of personalized medicine and how her father's cancer diagnosis played a role in her career. Welcome to another exciting episode of Oncology Overdrive :13 About Rubinstein :19 The interview 1:53 Can you tell us a little bit about your journey into this space? 2:04 So, they were in Seattle, and you were in New York … way before this pandemic happened were you working virtually that many years ago? 11:54 When you were first in the immunotherapy space at the beginning of your career, did you guess that it would have such a huge impact in the cancer space? 14:46 How did your father's cancer diagnosis influence the way you navigated your career in the oncology space? 24:26 Discussion on the importance of personalized medicine 35:12 Rubinstein's one pearl 42:20 How to reach Rubinstein 43:35 Julie Rubinstein, MBA, is the president of Adaptive Biotechnologies. She currently oversees Life Sciences Research, Clinical Diagnostics, Drug Discovery, Corporate Marketing and Business Development functions. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow us on Twitter @HemOncToday and @ShikhaJainMD. Rubinstein can be reached via email at jrubinstein@adaptivebiotech.com.    Disclosures: Jain reports she is a paid freelance writer for Lippincott. Rubinstein is the president of Adaptive Biotechnologies and has stock and other ownership interests in the company.

Whether we've fought our battles or helped family or friends with their own, cancer has likely impacted all of us. Malignancies are the leading cause of death among individuals under the age of 85 and are responsible for 9.5 million deaths globally each year, including an estimated 600,000 in the United States. But there are many reasons for optimism. Our deepening understanding of biology and the genetic root causes of disease are leading to better, earlier, and safer treatment options. The burgeoning field of liquid biopsies and other next-generation diagnostics allow us to detect cancers earlier and monitor recurrence in survivors, which promises to greatly improve survival rates. New therapeutic modalities ranging from genetic medicines to cell therapies to bispecific antibodies create opportunities for personalized treatments that are highly effective. It can be difficult for investors to keep track of the rapidly advancing scientific frontier, but there won't be an excuse this week. The American Association for Cancer Research (AACR) Annual Meeting 2021 is being held virtually from April 10 through April 15. As a scientific meeting, many companies will be presenting updates on key preclinical and clinical assets -- for the first time publicly, in some cases -- with a bias towards earlier-stage assets. Scientists across academic institutions, non-profit research centers, and industry will also gather to discuss challenges and opportunities for specific technologies ranging from the use of natural killer (NK) cells in cancer treatment, choosing biomarkers for liquid biopsy diagnostics, the role of artificial intelligence and machine learning in drug discovery and disease monitoring, and many more. Given the focus on early-stage assets, investors might not expect too many market-moving announcements. However, AACR will be a great time to check in on your investment thesis for a specific company or technology, get a better glimpse of the competitive landscape, and put new technologies on your radar for the next few years. For example, investors who kept pace with similar scientific meetings in recent years would have seen the massive market opportunities for liquid biopsies and potentially made life-changing investments in the pioneers. Topics discussed in this episode include next-generation diagnostics for tracking minimal residual disease (MRD), next-generation bispecific antibodies, and precision oncology. To view the full program, abstracts, and more, please visit the AACR Annual Meeting 2021 website. Publicly-traded companies mentioned in this podcast include Adaptive Biotechnologies, Agenus, Eli Lilly, Exact Sciences, Guardant Health, Illumina (via proposed acquisition of Grail), Invitae, Merus, NeoGenomics, and Xencor. 7investing Lead Advisors may have positions in the companies that are mentioned. This interview was originally recorded on April 5th, 2021 and was first published on April 8th, 2021. --- Send in a voice message: https://anchor.fm/7investing/message

William Li, M.D.: “We can now begin to test people who didn't have access to COVID testing earlier on to see if the photograph of the coronavirus is there, and that nails whether or not you've been infected.” Li, an internationally renowned physician and vascular biologist, joins mbg co-CEO, Jason Wachob, to discuss how to really know if you've ever had COVID, plus: *The link between COVID and vascular health* *How to eat your way to better blood flow* *What we know about COVID long-haul symptoms today* *Why T-cell tests may be more accurate than antibody tests* *How to self-assess your circulation & enhance it* Referenced in the episode: - The Angiogenesis Foundation website. - Li's book, Eat To Beat Disease. - Study from Germany showing 70% of people recovered from COVID have evidence for long-term heart damage. - Study showing soy food consumption associated with decreased risk of death in breast cancer survivors. - Small study showing those who were vaccinated had improvement in more long COVID symptoms. - T-cell test designed by Adaptive Biotechnologies, T-detect. - Li's Eat To Beat Disease Course with code mindbodygreen for a discount. Don't forget to submit your questions for our special 300th episode of the mindbodygreen podcast. We want to hear from our smart, curious, passionate listeners: Visit mindbodygreen.com/300 to contribute to this special interview and be entered into a giveaway of one of our MBG classes. Enjoy this episode! Whether it's an article or podcast, we want to know what we can do to help here at mindbodygreen. Let us know at: podcast@mindbodygreen.com. 

Shacey Petrovic, CEO and president of Insulet, explains how the company is giving people with diabetes new tools to manage their disease, a never-ending task that can require HUNDREDS of decisions per day. In this interview, Petrovic explains why research wasn't for her; why she decided to leave her first CEO job to join Insulet; and how the company is building the a glucose-delivery device that could convince people with diabetes to give up the certainty of the shot. In this episode, we also hear from Dr. Niki Panich, a practicing physician who is now CEO of a company that can help hospitals and health care facilities process their N95 masks on site. Dr. Panich will be a speaker on this Monday's DeviceTalks Clubhouse series. Finally, Chris Newmarker delivers the big news of the week involving Baxter, Adaptive Biotechnologies, Boston Scientific, Abbott, and AdvaMed.

In this week’s podcast, Medtech Insight's managing editor Marion Webb discusses a new monthly digital health roundup which will soon feature on Medtech Insight. Managing editor Reed Miller discusses reimbursement difficulties as it applies to remote cardiac monitoring. UK-based reporter Barnaby Pickering gives an overview of an interview he did with the chief medical officer of Adaptive Biotechnologies about its new T-Detect platform. Listen to the podcast via the player below: Reimbursement Questions Jeopardize Hillrom/Bardy Merger For more information on Medtech Insight and to start a free trial, click here: http://bit.ly/2w7LnlR Medtech Insight articles addressing topics discussed in this episode:

GeekWire editor Todd Bishop: On a cold, clear weekday morning last month, my quest to figure out whether I had COVID-19 in the early days of the pandemic took me to my back porch, where a mobile phlebotomist drew my blood. It had been 10 months since I was sick, and I had already received a negative result on a standard antibody test.  That earlier test was designed to detect the presence of the antibodies produced by the body’s immune system to ward off the virus that causes COVID-19. The negative result meant I probably didn't have COVID back in March. But given the possibility of a false negative in the antibody test, I wasn’t giving up that easily. And this test was different. This was a first-of-its kind diagnostic tool from Seattle-based Adaptive Biotechnologies, a company that develops technology to sequence the human immune system for the diagnosis and treatment of disease. T-cells are specialized cells that determine the human immune system’s response to disease. Adaptive says tell-tale signs of T-cell responses to specific diseases can be detected earlier and longer than antibody responses, and with a higher degree of accuracy. Adaptive Biotechnologies’ new test, called T-Detect COVID, was developed in partnership with Microsoft officially launched this week, under CLIA Clinical Laboratory Improvement Amendments federal regulations. The Food and Drug Administration is reviewing the T-Detect COVID test for Emergency Use Authorization (EUA). The test costs $150 plus lab fees. On this episode of the GeekWire Health Tech Podcast, we’ll talk with Lance Baldo, Adaptive's chief medical officer, to learn exactly how this test works, and what it could mean for diagnosing and treating a wide range of diseases. And yes, I’ll finally learn almost definitely, whether I had COVID or not.  See omnystudio.com/listener for privacy information.

Of all of the business discussions that Chad Cohen has had over the years, few are likely as memorable as the 20-second conversation he had with Zillow CEO Spencer Rascoff about midway into his 9-year career stint with the online real estate company. Cohen joined Zillow back in 2006 as corporate controller, a position that he says also had the added distinction of being the company’s first full-time finance role. Over the next 4 years, as Zillow’s back-office finance and accounting team took shape, Cohen’s responsibilities grew, allowing him to step into the role of vice president of finance. “I had been moving up the ladder, and it was right before we made the decision to go public—I remember Spencer coming into my office and saying, ‘You’re going to be CFO,’” says Cohen, who recalls Zillow’s CEO saying little more before exiting. For Cohen, the exchange signaled a 6- to 12-month transition that would enlarge his focus from being largely back-office to being both back- and front-office. “I had built an accounting and finance department, but this was a big step that required coaching from mentors and formal media training and IR experience,” says Cohen, who today views the Zillow IPO as only one of several Zillow milestones during his CFO tenure with the firm. Says Cohen: “I spent 4 years—or 16 earnings calls—as CFO, acquired about 10 companies, and raised somewhere between a half-billion and a billion dollars in capital from the public markets for Zillow Group.” Asked to recall a learning moment from his CFO years, Cohen says that he recalls waking up in a cold sweat during the 20- to 30-day period that immediately followed Zillow’s 2015 acquisition of Trulia. Having carefully crafted a 90- to 120-day postmerger integration plan, Cohen says, he realized that as the number of Trulia employee departures began to quickly escalate, “speed of integration” was going to play a plus-size role in the merger’s success. “Our retention bonuses—albeit very healthy and robust—were being offset by a very frothy employment market in San Francisco and even larger sign-on bonuses that we were having trouble competing with,” recalls Cohen. “I called my controller in a panic and said: ‘Hey, we have to do this faster because I think I see how the scenario is playing out—and it ain’t going to be pretty,’” remarks Cohen, who then instructed his team to “rip up” the 90-to 120-day plan, while accenting his new mandate for speed with the words “We’re going to do this now!” –Jack Sweeney

This podcast reviews the results of the whole genome sequencing study by Samur and colleagues that identified a genomic signature associated with superior survival in patients with newly diagnosed multiple myeloma. Disclosures: SAH has served on advisory boards or as a consultant for Adaptive Biotechnologies, Amgen, Celgene, Genentech, GSK, Oncopeptides, Sorrento; Takeda; has received research funding from Oncopeptides.     This JCO Podcast provides observations and commentary on the JCO article “Genome-Wide Somatic Alterations in Multiple Myeloma Reveals a Superior Outcome Group” by Samur et al. My name is Sarah Holstein, and I am an Associate Professor at the University of Nebraska Medical Center in Omaha, Nebraska in the United States. My oncologic specialty is plasma cell dyscrasias. I do not have any relationships to disclose related to these studies. The clinical heterogeneity of myeloma has long been appreciated as it is clear there is a broad range of disease behavior, with some patients having indolent disease and others having very aggressive disease. As a result, there has been significant interest in developing risk stratification systems that classify patients into different risk groups, thus providing some information about prognosis and potentially inform treatment decisions. Historically, staging systems were based on factors related to tumor burden. However, it is increasingly evident that the underlying disease biology is a key modulator of risk. Our ability to detect disturbances in the myeloma genome has changed dramatically over time. Metaphase karyotyping represents our lowest “power of magnification”. These studies led to the recognition that in general, hyperdiploidy involving odd-numbered chromosomes is associated with lower-risk disease while high-risk disease can involve translocations of chromosome 14, monosomy 13 and monosomy 17. Use of fluorescent in-situ hybridization (FISH) allowed for a higher power of magnification and identification of more subtle chromosomal abnormalities. Next, gene expression profiling studies utilizing small panels of genes, enabled classification of patients into different risk categories, although there was little concordance between the panels used in the various studies. The advent of deep whole genome sequencing technology has facilitated a much more “high-powered” view of the myeloma genome. In the article that accompanies this podcast, diagnostic bone marrow specimens were obtained from 183 patients enrolled in the IFM/DFCI 2009 study. This phase 3 study enrolled newly diagnosed transplant-eligible patients (up to age 65). All patients received three cycles of lenalidomide, bortezomib, dexamethasone (RVD) induction, underwent stem cell collection and then received consolidation with either 5 cycles of RVD or a single autologous stem cell transplant followed by 2 cycles of RVD. Of note, in the French portion of this study, all patients subsequently received one year of lenalidomide maintenance, while in the US portion, all patients received lenalidomide until progression. The French portion has already been published and showed a 14 month PFS benefit for the transplant arm compared to the non-transplant arm. Results from the US portion have not yet been released, but I would speculate that the PFS and OS for both arms will be superior to the French counterparts, given the existing data supporting the benefit of prolonged lenalidomide maintenance. Deep whole genome sequencing, with a median tumor depth of 75X, was used to interrogate the myeloma genome. Mutational signatures were based on identified single nucleotide variants, small insertions and deletions. The genomic scar score (GSS) was calculated based on allele-specific copy number alterations. A GSS of 5 or less was the cut-off for inclusion in the low GSS group. The goals of the study were to describe mutational loads and processes in order to establish genomically-defined subgroups, gain insight into patterns of evolution from clonal to subclonal mutations, and correlate these findings with clinical outcomes and more traditional risk factors. There were several key findings. First, mutational load varied amongst myeloma subgroups, with hyperdiploid myeloma having the lowest mutational load and t(14;16) having the highest mutational load. Second, analysis of mutational patterns led to identification of five separate mutational processes that contributed to eight mutational signatures. These five processes included: 1) an age-related process, 2) an AID/APOBEC process, 3) somatic hypermutation, 4) DNA repair, and 5) processes with unidentified etiology including the clock-like signature. Samur et al., found that these various processes contributed to different myeloma subgroups in different ways. For example, the age-related process was high in hyperdiploid myeloma, the APOBEC-related process was high in t(14;16) myeloma, the clock-like signature was high in t(4;14) myeloma and the DNA repair process was high in del(17p) and t(11;14) myeloma. Furthermore, analysis of these mutational patterns from a clonal vs subclonal perspective enabled insight into mutational development patterns of different subgroups of myeloma. Next, the GSS was correlated with mutational signature and clinical outcome data. The authors found that the frequency of a low GSS was higher in t(11;14) myeloma and lower in del17p, gain1q21, del1p and del13 subgroups. Patients in the low GSS group had a trend towards a longer median PFS and a statistically significant longer 4-year OS rate than other patients. In particular, patients with both low GSS and gain of chromosome 9 had a superior outcome compared to all other subgroups, with an OS probability of 100%. Patients with either low GSS and no gain(9) or with high GSS and gain(9) had intermediate outcome while those with high GSS and t(4;14), gain(1q) or no gain(9) had the worst OS. Although the numbers are quite small, an interesting finding was that for patients in the low-risk group (low GSS + gain(9)), there was a significantly superior PFS in favor of those patients in the transplant arm compared to the non-transplant arm. Overall, no statistically significant differences were found between the four subgroups and factors such as ISS stage, response, or achievement of MRD negativity.  The numbers in each subgroup were quite small though. Finally, the authors demonstrated that the low GSS could separate hyperdiploid myeloma into low-risk and high-risk subgroups. Overall, these studies are interesting because they provide insight into the mutational processes that drive different subgroups of myeloma and offer a potential method by which to differentiate low-risk hyperdiploid myeloma from high-risk hyperdiploid myeloma. The finding that there was a difference in PFS for patients who underwent transplant vs no transplant in the low-risk group (low GSS, gain(9)) is very intriguing. There has been much discussion centered around whether low-risk patients really “need” to go through a stem cell transplant since in general their outcomes are good. The present study, aside from highlighting the fact that our traditional methods of identifying low-risk disease are likely inadequate, raises the hypothesis that patients with low-risk disease may benefit even more from transplant than other risk groups. However, it is noted that this subgroup consisted of only 28 patients. In addition, it is not clear from the manuscript whether patients were in the US vs French portion of the study, thus differences in study design (i.e., lenalidomide maintenance duration) could impact PFS findings. Clearly, this type of whole genome sequencing analysis will need to be applied to additional prospective studies in order to validate the novel risk stratification system. For now, these results are not practice-changing. However, they provide a potential glimpse into the future, where whole genome sequencing analysis is performed as readily as FISH analysis, and where enrichment strategies using genomic markers are used to design clinical trials. Aside from studies evaluating the use of venetoclax in t(11;14)-positive myeloma and other studies focused on high-risk disease that encompass a variety of high-risk chromosomal abnormalities, the field of myeloma has not yet moved into an era of precision medicine. Whether whole genome sequencing can finally usher us into that era remains to be determined. While this plasma cell-centric analysis is certainly revealing, it is likely that in order to maximally target myeloma, the genomics analysis must be coupled with an equally in-depth understanding of the host’s immune system. This concludes this JCO Podcast. Thank you for listening.

The AI Eye Episode 368: Microsoft (NasdaqGS: $MSFT) and Adaptive Biotechnologies (NasdaqGS: $ADPT) Launch ImmuneCODE COVID-19 Database

The AI Eye Episode 368: Microsoft (NasdaqGS: $MSFT) and Adaptive Biotechnologies (NasdaqGS: $ADPT) Launch ImmuneCODE COVID-19 Database

Hệ miễn dịch của con người được tạo thành từ hàng triệu tế bào "T", nhận biết và giúp chống lại các v irus xâm nhập cơ thể. Microsoft và Adaptive Biotechnologies đã tạo ra một xét nghiệm giúp xác định và phân tích cách các tế bào này phản ứng với COVID-19. Kết quả sẽ giúp các nhà nghiên cứu cải thiện phương pháp chẩn đoán, điều trị và vaccine.

In the world of diagnostic tests for COVID-19, there are two main approaches: PCR tests, which detect the presence of the live virus; and serology tests, which detect antibodies that indicate whether someone has recovered from the disease. But could there be a third way? Two companies based in the Seattle region, Microsoft and Adaptive Biotechnologies, are working together to try to create a better diagnostic test. Joining us to explain the initiative are Peter Lee, Microsoft corporate vice president of AI and Research, and Adaptive CEO Chad Robins.  At a basic level, Microsoft and Adaptive are looking for the unique signature associated with COVID-19 in the specialized cells that determine the human immune system's response to the disease. Once that signature is identified, they say, it could lead to a new test that would detect the tell-tale signs of the disease in others, providing a new form of diagnosis. The companies last week launched a virtual clinical study, seeking 1,000 people across the country who have been diagnosed with, exposed to, or recovered from COVID-19. The study is called “ImmuneRACE,” for Immune Response Action to COVID-19 Events. It focuses on 20 major metro regions in the US.. As of earlier this week, the study had more than 100 participants out of the 1,000 it’s seeking.

Chad Robins, CEO and Co-founder of Adaptive Biotechnologies, discusses their recent partnership with Microsoft to decode the immune system's response to CODVID-19 and develop better diagnostic tools and their partnership with Amgen to develop potential antibody therapies to treat the disease. Chad also shares how the medical field is adapting and facing new challenges during this pandemic. 

Immunotherapy and Policy. How can the FDA evolve to help advance and support novel approaches to medicine? How does the field of immune-driven diagnostics serve as a case in point for the need for evolution in existing regulatory frameworks?Special guests:Meghan GutierrezChief Executive OfficerLymphoma Research FoundationLeo David Wang, M.D., Ph.D.Assistant Professor, Department of Immuno-OncologyAssistant Professor, Department of PediatricsCity Of HopeThis series is brought to you ad-free by Adaptive Biotechnologies

Beyond Immunotherapy. The present and future of immune-driven medicine; toward an understanding of the immune system as the driver of solutions for treatment, prevention, and diagnosis of disease; identifying and creating responses to specific immune activation pathways.Special guests:Meghan GutierrezChief Executive OfficerLymphoma Research FoundationLeo David Wang, M.D., Ph.D.Assistant Professor, Department of Immuno-OncologyAssistant Professor, Department of PediatricsCity Of HopeThis series is brought to you ad-free by Adaptive Biotechnologies

A Brief History of Immunotherapy. CAR-T, t-cell augmentation, and immunotherapy in general over the past decade. We will talk about why is this approach so compelling, and what its limitations have been to date.Special guests:Meghan GutierrezChief Executive OfficerLymphoma Research FoundationLeo David Wang, M.D., Ph.D.Assistant Professor, Department of Immuno-OncologyAssistant Professor, Department of PediatricsCity Of HopeThis series is brought to you ad-free by Adaptive Biotechnologies

In this podcast moderated by Dr Michael Kalos, Janssen Oncology, you will hear a panel discussion from the 2019 IO Combinations 360° conference. Topic points include: What are the new opportunities in cell therapy for combinations?What the challenges are going to be with the microenvironment?What is being done to engineer cell therapy?How do you develop CARs and TCRs that deliver payloads?How do you manufacture all of this beyond mouse models to figure out how to effectively do this in patients?How do you actually go about designing trials and testing hypothesis?How do you create the regulatory framework to do these types of studies?How do you engage with regulatory agencies to get these things moving? Panelists include: Sharon Benzeno, PhD, MBA, Adaptive BiotechnologiesChaohong Fan, MD, PhD, FDABruce Levine, PhD, University of PennsylvaniaMark Stewart, PhD, Friends of Cancer ResearchBahram Valamehr, PhD, Fate Therapeutics To learn more about the upcoming IO Combinations 360° conference please visit, www.iocombinations360.com

Chad Robins is a Cornell grad and Wharton School MBA who was working in real estate finance a decade ago when he was approached with a business idea by his brother, Harlan Robins, head of the Computational Biology Program at the Fred Hutchinson Cancer Research Center. As Chad Robins recalled, "When he called me up in 2009 and said, 'Hey I want to start a business, I've figured out how to sequence T-cells at a high throughput,' I was like, 'Yes, I'm in!' and then I went to Wikipedia and I'm like, 'What the hell is he talking about?' I don't know the difference between a T-cell receptor and a T-bone steak." A decade later, the company they created, Adaptive Biotechnologies, is using the genetic code of the immune system to change the diagnosis and treatment of disease. It’s valued at more than $1 billion. It has partnerships with industry giants Microsoft and Genentech, and this week it filed raise $230 million in an initial public offering. On this episode of the GeekWire podcast, we’ll get the inside story of Adaptive Biotechnologies and share what we learned in its IPO filing. Correction 6/3: Chad Robins and Harlan Robins hold about the same amount of equity in the company, which wasn’t apparent from the IPO filing because some of the stock is held in trusts. We've update the audio to remove this portion of our discussion.

The co-founders of Adaptive Biotechnologies on immune sequencing.

Chad Robins is the CEO of Adaptive Biotechnologies. His company, which he co-founded with his brother Harlan, has received over $400 million in funding as it drives ground-breaking research in cancer and other immune-mediated diseases. Chad simplifies his role as a CEO into three categories and breaks down this complex industry for everyone to understand. Listen to this riveting episode and hear how he moved from investment banking to biotech, what working with his brother is like and how 100 days spent in the wilderness is what influences his leadership style to this day.

Today in FirstWord:

CHI interviewed Dr. Catherine Sanders, Director and Team Lead of Scientific Liaisons at Adaptive Biotechnologies on the utilization of high-throughput sequencing and expert bioinformatics profiling T-cell and B-cell receptors, also known as immunosequencing, to enable the development of a new generation of cancer immunotherapies. Discussion questions include: 1. Can you tell us a bit about Adaptive Biotechnologies, its origins, and where you are as a company now? 2. Can you please tell us about immunosequencing, and its applications in preclinical and clinical settings? 3. You are giving a luncheon presentation during the Cancer Immunotherapy and Combinations meeting, June 15-16, 2016 in Boston. Can you give us an idea of what you hope to convey to attendees during this lecture? 4. What challenges exist that may be overcome in the near future? What does the future of Adaptive and immunosequencing look like? For more information, please visit http://www.WorldPreclinicalCongress.com/Cancer-Immunotherapy-Combinations/